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Abstract
With aging, keratinocytes have diminished proliferative capacity resulting in atrophic skin
with reduced barrier function. This investigation evaluates the effect of daily topical
applications of a novel high-molecular weight hyaluronan cream (HA-PE) on keratinocyte
renewal and epidermal thickness. Unmodified hyaluronan and HA-PE were mixed
separately into a vehicle cream. Each topical formulation was applied daily onto the shaved
backs of aged female C57BL6 mice. Full-thickness biopsies of treated skin were obtained
for analysis of keratinocyte proliferation, keratinocyte differentiation, and local
inflammation at days 1, 5, and 10 of cream application. In addition, a cardiac puncture was
performed for serum C-reactive protein analysis. The HA-PE group exhibited the highest
level of keratinocyte proliferation and epidermal thickness at all time points. There was no
significant difference in keratinocyte differentiation or local/systemic inflammation
between groups. Thus, topical HA-PE cream is a novel skin care technology that increases
epidermal thickness through enhanced keratinocyte proliferation/renewal.

Keywords topical hyaluronan, topical hyaluronic-acid, keratinocyte proliferation,
epidermal thickness, skin renewal, skin aging; hyaluronan-phospholipid
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Chapter 1: Introduction
Epidermis
Structure and Function
The skin is a specialized organ derived from both ectoderm and mesoderm precursors
during embryogenesis. Skin has many important roles including providing a barrier to the
external environment, sensation, immune surveillance, thermoregulation, endocrine
functions and control of insensible fluid loss [1] . The integumentary system structure and
physiology evolves with senescence. In contrast to young skin, aged skin is characterized
as atrophic, dry, wrinkled, and fragile. However, it is not only the external appearance of
skin that deteriorates with age- so does its function [2-4].

Anatomically, the epidermis (ectoderm) and dermis (mesoderm) are the primary layers of
the skin. The epidermis is avascular and receives oxygen and nutrients by passive
diffusion from the underlying dermis. In humans the epidermis forms a sinusoidal pattern
with projecting fingerlike extensions, termed rete ridges, into the underlying dermis. The
rete ridges provide an increased surface area of contact with, and thus adherence to, the
underlying dermis. With aging, rete ridges become effaced and the epidermis is more
vulnerable to external mechanical forces such as friction and shearing [3]. Simple skin
tears, from innocent trauma such as removing an adhesive bandage for example, can
result in significant morbidity for the elderly [5].

The epidermis is classified histologically as a stratified squamous epithelium. In humans,
there are four identified layers of the epidermis. These layers are from deep (resting on
the skin basement membrane (BM)) to superficial (exposed to the external environment):

2
stratum basale, stratum spinosum, stratum granulosum, and the stratum corneum (SC).
The epidermis also lines dermal appendages including various sebaceous/eccrine sweat
glands and hair follicles. This feature provides a reservoir for epidermal regeneration
following wounding or extensive epidermal trauma such as a partial-thickness burn.

Young epidermis possesses a robust renewal capacity. The keratinocyte is the principal
cell in the epidermis. Keratinocytes are generated from stem-cell progenitors lining the
basal layer of the epidermis and the bulge of the hair follicle [6]. With respect to the
epidermis, ongoing replication pushes terminally differentiated keratinocytes towards the
SC. The SC is characterized by anucleate corneocytes embedded in a laminar lipid matrix
[7]. The thickness of the epidermis and concentration of natural moisturizing factors
(NMF) improve the barrier role of skin [7, 8]. Flaggrin and hyaluronan (HA) are two
examples of NMF important to SC hydration [7]. Desquamation, a process of shedding
the outermost layer of the SC, allows the cornified envelope to balance the replicative
potential of the stratum basale. The typical transit time of a keratinocyte through the
epidermal layers is four weeks [1]. The self-renewal capacity of the epidermis is therefore
tightly regulated to preserve homeostatic balance. However with aging, a new set-point is
established as the thickness of the epidermis is diminished and this reflects a reduced
proliferative capacity [4].

Between the cellular components of skin lies the extracellular matrix (ECM). The
epidermal

ECM

is

composed

of

proteoglycans

and

glycosaminoglycans.

Glycosaminoglycans (GAG) are formed from disaccharide units of an amino and uronic
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sugar. The simplest and most abundant GAG in the skin is HA. HA is found in the
intercellular ECM and forms pericellular coats (discussed later in this chapter) around
keratinocytes. Proteoglycans differ in that they contain a protein core with variable
attachment of glycosaminoglycans. The BM, a specialized part of the ECM, separates the
stratum basale from the dermis and is composed primarily of laminin, type IV collagen,
and proteoglycans [9]. The differential structure of the BM helps identify the polarity of
the epidermis. Overall, proteoglycans and GAG provides a structural framework to
support cellular components of skin. As with keratinocytes aging, aging also affects the
constituents of the ECM. Further details of GAG and aging are discussed later in this
chapter.

Along with the keratinocyte, the epidermis contains other resident cell types including
Langerhans cells, melanocytes, and Merkel cells. These cells are responsible for immune
surveillance through antigen-presentation, protection from ultraviolet light exposure, and
mechanosensation respectively.

Keratinocyte Proliferation and Differentiation
Keratinocyte proliferation and differentiation provide a foundation for epidermal repair
and renewal. Keratinocyte renewal and maturation is identified by differential expression
of cell surface markers as the keratinocyte proliferates, migrates to and ultimately
integrates into the stratum corneum. Cutaneous keratins form intermediate filaments that
provide structural support to keratinocytes. Different keratins are expressed during
keratinocyte proliferation/differentiation. For example, keratin cell surface expression of
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K5/K14 are hallmarks of epidermal proliferation and K1/K10 expression indicates
suprabasal terminal differentiation [10, 11]. Additional proteins such as Ki67 are also
commonly used to identify cellular proliferation [12-14]. A complex interaction of
mechanical

and

cytokine

ECM

signaling

regulates

the

keratinocyte

proliferation/differentiation program [10, 15].

The basal layer of the epidermis contains epidermal proliferative units (EPU) [1, 16-18].
An EPU is formed from a single adult stem cell and its progeny. Epidermal adult stem
cells can be found in niches in the basal layer of the epidermis and the bulge of the hair
follicle. Through symmetric and asymmetric cell division the epidermal stem cell
progenitor can replace itself and produce a transit-amplifying (TA) intermediate stem
cell. The TA intermediate has a finite number of self-renewal cell divisions before being
committed to a terminal differentiation pathway (represents keratinocytes with no further
proliferative capacity). The adult stem cell forming the EPU can be identified using
certain markers such as Oct4, which is expressed by the immortal stem cell but down
regulated in the differentiated progeny (for example, TA intermediate stem cells)[19].
The self-renewal capacity of the epidermis is dependent on the organization and
functional activity of the EPU. Various growth factors (epidermal growth factor (EGF)
[20], keratinocyte growth factor (KGF) [12, 20], transforming growth factor beta
(TGFβ)[21]), GAGs (HA), and mechanical stimuli [15] have been implicated in
regulating keratinocyte growth.
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Hyaluronan
HA is an ubiquitous ECM non-sulphated GAG present in mammalian tissues. Although
first discovered in the vitreous humor of the eye in the 1930’s [22], the majority of total
body HA is present in the skin [23, 24]. HA consists of linear chains of repeating
disaccharide units of N-acetyl-D-glucosamine and D-glucuronic acid [25, 26]. Despite a
simple chemical structure, endogenous HA can exist in a variety of conformations from
simple extended chains to complex random entanglements [27, 28]. HA is also highly
hydrophilic and can bind 10,000X its own weight in water [29, 30]. Both extracellular
and intracellular HA exist, however the focus of this thesis will be limited to discussion
of extracellular HA. Limited knowledge exists regarding the function of intracellular HA
in epidermal rejuvenation and integrity. In comparison, extracellular HA is known to be
important in preserving epidermal hydration as well as providing a scaffold for
keratinocyte communication, proliferation, and differentiation.

Extracellular HA exists in a number of functional forms including cell associated
pericellular coats, as extracellular structures bound to proteins, or as a small circulating
pool of unoccupied HA [23, 31]. HA can modulate cellular activity through interaction
with a variety of cell-surface receptors. CD44 is the major constitutively expressed HA
receptor of the epidermis [23]. RHAMM is an additional HA receptor which is expressed
during tissue inflammation and tissue repair [32]. HA receptor affinity, arrangement and
downstream signaling cascades are influenced by the size of bound HA. CD44 binds HA
through a single extracellular link domain [33]. High molecular weight HA (HMWHA)
has multivalent sites for synchronous interactions with multiple CD44 receptors.
HMWHA has thus been shown to induce clustering of CD44 receptors [34]. Yang et al.
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(2012) through in vitro models showed that treatment with low molecular weight HA
(LMWHA) disrupted the amount of CD44 clustering present on cells [35]. Thus, CD44
clusters create a configuration partial to HMWHA (anti-inflammatory) signaling, which
appears inherently different to the single ligand-receptor interactions (pro-inflammatory)
effects of LMWHA [35].

Hyaluronan Homeostasis
HA is synthesized in the inner surface of the plasma membrane by HA synthases (HAS)
[24, 31]. Three different isoforms of HAS, all of which are found in skin, have been
identified (HAS1, HAS2 and HAS3) [36]. HAS2/3 are predominantly expressed by
keratinocytes, whereas HAS1/2 are expressed by fibroblasts [37]. Each synthase isoform
shares approximately 70% identical amino-acid sequences, but functionally each HAS
produces HA of differing lengths [33]. HAS1/2 are known to produce HMWHA.
Whereas, HAS3 produces shorter LMWHA [27, 33]. Each HAS is differentially
expressed indicating distinct modes of regulation of expression [36, 38]. HAS2, for
example, is crucial for both embryogenesis and life [27]. In terms of skin, cutaneous
injury studies demonstrate increased HAS2/3 mRNA expression by mouse keratinocytes
[39]. In vivo HAS1/3 null mice show impaired HA accumulation following cutaneous
wounding providing further evidence for the importance of HAS3 in the acute
inflammatory response of keratinocytes [37]. All HAS enzymes extrude nascent HA into
the extracellular environment through an intra-protein pore present in their molecular
configuration [28].
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Dynamic HA metabolism balances ongoing HA synthesis. In vivo studies in rabbits
demonstrated that the half-life of free HA is short, quoted at approximately 3-5 minutes
in blood [23, 40], 24-72 hours in skin [29, 31, 41] and 1-3 weeks in cartilage [29]. In
contrast, the stable configuration of HMWHA appears to resist rapid hyaluronidase
degradation [23]. The majority of HA degradation occurs in the lymphatics, but can also
take place in the host tissue and spleen/liver sinusoids [23, 31, 40, 41]. HA is fragmented
into smaller units by either hyaluronidases (HYAL) [24, 25]. Six primary HYAL have
been identified which act by hydrolyzing the β (1-4) linkages between N-acetyl-Dglucosamine and D-glucuronic acid [29]. [33]. HYAL2 specifically hydrolyses HMWHA
into smaller oligosaccharides which are further degraded in lysosomes by HYAL1 [33].
Fragmented HA units are subsequently cleared through lysosome endocytosis and
glycosidase degradation into terminal sugars. Alternatively, HA can be metabolized by
free-radical metabolism [24]. The process of HA degradation is partially mediated by
HA-receptor interactions that differ depending on the tissue site. For example, HA
binding to CD44 may signal HA endocytosis in the skin whereas LYVE-1 receptor
activation provides the equivalent stimulus in lymph nodes [27].

Pericellular coats
Using erythrocyte exclusion assays, Clarris et al. (1968) identified a cleared zone
surrounding human synovial cells which they described as analogous to a bacterial
capsules [42]. Treatment with hyaluronidase obliterated this potential space, validating
the association of HA to the integrity of pericellular coats [28, 42, 43]. HA associates
with the pericellular membrane through into the plasma membrane by interactions with
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HA receptors such as CD44, and nascent chain attachments to HAS2/3 [27]. Tammi and
Tammi (2008) have made important contributions to our understanding of HA
pericellular coats. Using cells transfected with a green fluorescent probe GFP-HAS3,
their group demonstrated that the presence of HAS in the cell membrane promoted the
formation of plasma membrane protrusions [43] (Figure 1). The plasma membrane
protrusions add both surface area and complexity to the three dimensional structure of the
HA pericellular coat (Figure 2).

9

Figure 1. Hyaluronan dependent pericellular coats. Confocal images of hyaluronancoated microvilli on live cells transfected with green fluorescent protein (GFP)hyaluronan synthase (HAS)3. Erythrocyte exclusion space and GFP-HAS3 in cell
protrusions around a live cell are shown (A), the use of a hyaluronan binding probe
demonstrates HA associated with the same cell (B), a composite image (C). (D-I) Timelapsed images of the same cell treated with Streptomyces hyaluronidase (10 TRU/ml)
before treatment (D) and 1 (E), 2 (F), 3 (G), 4 (H) and 5 (I) min post-treatment. Arrows
indicate microvilli projections resistant to degradation (I). Red, hyaluronan; green
particles, erythrocyte autofluorescence; green in cell, GFP-HAS3 [43]. Image copyright
was approved by SAGE publications (Appendix A).
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Figure 2. Schematic diagram of proposed structure of pericellular hyaluronan coats.
(A) Model whereby hyaluronan chains (red) attach directly into the plasma membrane
(green) through hyaluronan receptors, hyaluronan synthases, or direct insertion creating
an exclusion space for erythrocytes (orange). (B) Tammi and Tammi model whereby the
presence of hyaluronan promotes plasma membrane protrusions creating a more complex
scaffolding of the pericellular coat [43]. Image copyright is approved by SAGE
publications (Appendix A).
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Further study of the HA-dependent pericellular coat revealed its structure and function
[28] [Figure 2]. The pericellular coats traps proteins, growth factors and other signaling
factors in close proximity to the target cell that can stimulate downstream signaling
cascades through target growth factor receptors and dynamic HA-receptor interactions. In
addition to the interactions between CD44-HA, the HA pericellular coat can alter cell
behavior through mechanotransduction signaling.

For example, endothelial HA

pericellular coats are known to be important in inducing intracellular nitric oxide
production secondary to shear stress produced from blood flow [28]. The cell coat is fluid
and can be rapidly formed or destroyed depending on the state of the tissue [28]. Thick
HA pericellular coats can form from a linear orientation of HA caused by the negative
valences from proteoglycan associations, such as aggregan in chondrocytes and versican
in fibroblasts [28]. The presence of proteoglycans can contribute to thick pericellular
coats. However, epithelial cells also form 20 µm thick coats with minimal aggregation of
proteoglycans [43].

Plasma membrane CD44 is vital to pericellular coat formation. Blocking CD44
expression through antibodies, CD44-siRNA, and knockout (KO) CD44-/- models has
been shown to result in abnormal histolocalization of HA [44]. Interestingly CD44 KO
mice show normal epidermal development and thickness, perhaps identifying
compensation from other HA signaling pathways contributing to epidermal development
[44].
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Molecular weight and function
The multitude of identified functions of HA depend on its molecular size, concentration
and configuration [23, 25]. The role of different molecular weight HA in skin hydration,
aging, and acute and chronic wound repair been studied extensively [23, 30, 45-48].

HMWHA:
The rheological properties of HMWHA are known to improve the overall quality and
immune barrier function of skin. In terms of HA and wound healing, interestingly fetuses
prior to 24 weeks gestation have markedly high expression of HA and are found to heal
cutaneous wounds without scarring [30, 46, 47]. The majority of endogenous native HA
is HMWHA (105 – 107 Daltons) which forms random coils and entanglements depending
on the size and molecular associations [23, 27]. Endogenous HMWHA is particularly
present in pericellular coats [25, 28, 43] that create a fluid scaffold for enhanced cell
motility and as noted above HA modulates cell-to-cell adhesion, migration, proliferation,
and differentiation [23, 45, 49] through interactions with CD44 receptors [32]. Overall,
HMWHA functions are anti-angiogenic, anti-inflammatory and immunosuppressive [35].
HMWHA is known to prevent immune cell recognition and inhibit phagocytosis by
macrophages [50]. Studies using the naked mole rat model suggest that HMWHA also
infers cancer resistance [51]. HMWHA can act as a free radical scavenger, the toxicity of
free radicals is diminished because reactive oxygen species (ROS) complex with the
double bond in the D-glucuronic acid unit of HA [52].

LMWHA:
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Under certain tissue states, smaller HA fragments (low molecular weight HA, LMWHA)
are produced de novo by hyaluronidase degradation or oxidative metabolism of
HMWHA. LMWHA activates the inflammatory cascade and promotes angiogenesis in
response to tissue injury [23, 35]. The diverse spectrum of processes that involve HA,
highlight its importance to preserving overall skin health.

Aging skin and hyaluronan
Skin aging is a combination of the culmination of intrinsic and extrinsic influences [53,
54]. Intrinsic aging, or chronological aging, refers to aging related to cellular DNA
damage and altered cellular biosynthetic function. Many theories have been developed to
explain features of intrinsic aging. For example, the “oxidative stress theory” refers to
impairment in the cell’s regulatory genetic program to reverse oxidative damage incurred
in cellular DNA [55]. Alternatively, the “mitotic clock” theory also is used when
discussing chronological aging, whereby telomere shortening of DNA with copious
replication cycles is an inevitable cause of aging [53]. External factors such as sun
exposure influence the degree of extrinsic aging. Photo-damage can also increase the
amount of cellular oxidative damage that is poorly tolerated in aged skin given an
intrinsic deficiency of anti-oxidant cellular machinery. The functional consequences of
extrinsic and intrinsic aging are shared and include epidermal barrier dysfunction,
atrophy, xerosis [3], delayed wound healing [2, 3], as well as an increased susceptibility
to inflammatory or infectious pathologies and irritant contact dermatitis [2, 52, 53, 56,
57]. Overall with aging, skin integrity is diminished.
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Histological changes in both the aged epidermis and dermis are evident. Both skin layers
become atrophic [2, 3, 54, 55] with reduced cellularity [2, 55] as shown by decreased
numbers of melanocytes, Langerhans cells and fibroblasts [53]. The thinner epidermis
characterized in aged skin is due to a decrease in proliferation of basal keratinocytes [14,
22] and a longer SC transit time [4]. In young people, the SC transit time averages 20
days, whereas in elderly people it can be greater than 30 days [4]. Branchet et al. (1990)
[4] used punch biopsies from a cross-sectional sample of healthy individuals age 20-80 to
demonstrate the integumentary histological changes that occur with aging, including
decreased epidermal thickness. Some studies have shown that despite decreased
proliferation, keratinocyte differentiation appears unchanged with aging [58].

The

regular honeycomb keratinocyte pattern of youthful skin becomes irregular with aging
[54]. Flattening of the dermoepidermal junction is also a histological hallmark of aged
skin [2, 53, 58]. In the dermis, aging results in decreased matrix synthesis by fibroblasts
[14, 57, 58], decreased collagen type 1 expression [55], increased matrix
metalloproteinase (MMP) expression and increased expression of collagenases [55].
Overall, dermal atrophy [3, 55, 58] and disorganization of the collagen/elastin framework
contributes to skin laxity, fragility and poor wound healing [3, 58].

The relationship of HA and aging is well established in both normal skin and pathological
conditions. Studies involving patients with conditions of premature aging, such as
Werner’s syndrome, have provided further evidence of the relationship of HA and aging
[23, 59]. Skin biopsies from patients with progeria show abnormal GAG metabolism and
reduced HA content [59]. In addition, patients with progeria have increased HA
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metabolism reflected in higher urinary excretion of HA [59]. High circulating levels of
fetal HA drop shortly after birth and are thought to remain in steady state until
senescence [23, 60]. With aging, circulating levels of HA rise again [23] with notable
changes in the histolocalization of HA [60]. In terms of the epidermis, the quantity of HA
present in the epidermis decreases with age [23]. Dermal HA quantity remains constant
throughout the lifespan, but becomes less extractable and fluid with aging [23].
Replacement of HA has been shown to improve some of the aesthetic and functional
deficiencies of aged skin.

Controversy exists whether it is possible to stimulate senescent keratinocytes to undergo
mitotic division to regenerate the skin barrier [55]. Growing evidence is emerging in
favor of the mitogenic capability of HA in senescence [25]. Wohlrab et al. (2013)
support the finding that HA has a stimulatory effect on keratinocyte and fibroblast
proliferation in vitro [61]. Further animal studies show that topical application of
HMWHA rejuvenates the skin through CD44-dependent expression of markers of
keratinocyte proliferation and differentiation [56, 62, 63], as well as markers of SC
integrity including the NMF marker Flaggrin [56]. HA is involved in dissociating basal
keratinocytes from underlying substratum which promotes cellular replication [30]. Quan
et al. (2013) [14] has shown that following injection of a cross-linked HA filler into
individuals older than 70 years there was a 19% increase in epidermal thickness and
increased Ki67 (keratinocyte proliferation marker) staining one-month post-injection.
This study also provided evidence that HA injections also stimulated fibroblasts to
undergo functional activation thus enhancing the structural support of the underlying
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dermis [14]. Overall, it appears that replacement of HA which is lost in the aging process
has beneficial effects on skin health.

HA and Cutaneous Immunobiology
Skin provides a critical barrier role in protecting from external insults. Overall, cutaneous
immunobiology is complex and tightly regulated. Innate and acquired immunity signaling
cascades form the backbone to the host immune defense system [64]. Innate immunity
provides a rudimentary mechanism whereby professional phagocytes such as neutrophils,
mast cells, and macrophages recognize danger signals from infectious, physical, or
chemical insults [65]. Keratinocytes are some of the first cells to secrete proinflammatory cytokines in response to a threatening stimulus. The ensuing temporary
inflammatory reaction allows the individual to combat the potential damage to tissues.
However, prolonged or uncontrolled inflammation can be detrimental. Cytokines are
potent chemical messengers of the immuno-inflammatory cascade. The ultimate tissue
effect of the immuno-inflammatory cascade depends on a multitude of factors including
the inciting stimulus and the presence of other cellular mediators or receptors [64].
Acquired immunity refers to more sophisticated and targeted cell-mediated immunity
involving T cell and B cell subsets. The discussion of this thesis will be limited to
mediators of innate immunity and the local tissue inflammatory response.
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Macrophages
Macrophages are the most abundant immune cell population in skin [66]. Macrophages
may either be recruited from a pool of circulating monocytes or alternatively exist as
tissue-resident macrophages. Macrophages can be identified by expression of cell-surface
markers including F4/80 [67], CD11b and CD18, CD68, and Fc receptors [68].
Macrophages are professional phagocytes which ingest and process foreign material and
necrotic debris [68]. Through the production of various cytokines macrophages stimulate
other immune cells such as dendritic cells, neutrophils, mast cells, T lymphocytes and
lymphoid cells to assist with neutralizing threats to skin homeostasis [66].

Investigators have proposed that macrophages are heterogeneous and exhibit functional
plasticity defined as polarity (e.g. M1 and M2) based upon different transcriptomes and
markers [66, 68]. For example, M1 macrophages are generally pro-inflammatory, play a
role in anti-tumor immunity, help defend against bacteria, protozoa and viruses and are
present in early stages of response to injury processes [68, 69]. In contrast, M2
macrophages predominate in later stages of wound repair, and are involved in tissue
healing and the resolution of inflammation, through secreting anti-inflammatory
cytokines such as IL-10 [69]. Both infection and inflammation from sterile tissue damage
provoke expression/accumulation of proinflammatory signals that attract macrophages.
Macrophages express receptors that are part of the Damage-associated molecular pattern
(DAMP) detection that include Toll-like receptors (TLRs, TLR2,4 also bind to HA),
HA/motility receptors such as CD44 and RHAMM, and pattern recognition receptors [66,
68, 70]. In later stages of tissue repair the ratio of M1 macrophage pro-inflammatory
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phenotype transitions to favoring the M2 macrophage anti-inflammatory and growth
promoting phenotype. One result is, targeting of macrophage phagocytosis to apoptotic
neutrophils, which contributes to resolution of inflammation [66].

TNFα
TNFα is a potent pro-inflammatory cytokine that is released by activated M1
macrophages [71] and Langerhan’s cells [72]. TNFα is a cytokine involved in both the
inflammatory phase of wound healing as well as acute and chronic skin inflammation. In
addition, elderly patients have a two-fold to four-fold elevation in baseline levels of
inflammatory markers [72] which could represent a state of low-grade inflammation
secondary to systemic disease common in the elderly [73]. TNFα activates multiple
downstream pro-inflammatory signaling pathways contributing to blood vessel dilatation,
enhanced neutrophil lifespan and function, and induction of keratinocyte apoptosis [64,
71]. Researchers have searched for ways to temporize the detrimental tissue effects of
prolonged inflammation, such as that seen in patients with cutaneous burns, by blocking
TNFα activation. A rat model of partial-thickness burns, has shown promising results
using topical HMWHA conjugated to an anti-TNFα antibody to reduce inflammation
compared to an anti-TNFα antibody alone [71]. Cutaneous ulcers also demonstrate
increased TNFα levels and provide an additional model of chronic wounding and
prolonged inflammation. Acute wounding in patients with previous ulcers, have shown to
have elevated TNFα up to day 7 post-wounding compared with age-matched controls
[74]. The kinetics of TNFα expression can create challenges in using it as a marker of
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inflammation in research. Initially thought to have a brief and transient acute response
during inflammation, researchers have shown following wounding TNFα can remain
elevated for up to a week or longer [75]. Clinically, patient groups with burns and ulcers
demonstrate that elevated TNFα is both a marker of and target for clinical intervention in
cases of impaired cutaneous healing and prolonged inflammation.

HA and Inflammation
HA fragments:
As previously mentioned, the functional effects of HA depend on its molecular size,
localization, and availability of specific receptors [25]. HA fragmentation is known to be
an important early regulator of inflammation that is part of the DAMP response to tissue
stress. Elevated HA levels and likely fragmentation occur in rheumatoid joints, lung
disease, as well as inflammatory bowel, liver, and vascular disease [50]. Fragmented or
LMWHA produced from reactive oxygen species (ROS), catabolic degradation, or de
novo synthesis through HAS3 contributes to the pro-inflammatory milieu in early stages
of tissue injury [50]. Noble et al. (2010) and others (Savani et al. (2005)) have studied the
pathogenic role of HA in sustaining inflammation and fibrosis in a model of noninfectious fibrotic lung injury [70, 76]. The profile of HA fragment accumulation mirrors
the peak inflammatory response following damage to the ECM in a lung injury model.
These fragments activate macrophages and signal expression of a subset of downstream
pro-inflammatory cytokines through the transcriptional regulator NF-κβ: these function
to recruit other mediators of the innate immuno-inflammatory cascade.

When HA

receptor-mediated endocytosis of these pro-inflammatory HA fragments are blocked
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unremitting inflammation and consequent fibrosis ensues that eventually results in tissue
destruction.

Thus, HA fragments regulate the innate immuno-inflammatory response through different
receptors. For example, signaling through CD44 in murine macrophages augments
TNFα, IL-1β, and IGF-1 production [50, 77]. TNFα activates fibroblasts further
promoting collagen deposition, which if uncontrolled can lead to fibrosis [77]. In
contrast, HA fragment interactions with TLR-2 and -4 are proinflammatory, whereas
HMWHA interactions with TLR-2/4 are anti-inflammatory [78, 79]. CD44 -/macrophage models have a blunted inflammatory response, whereas double TLR-2 and 4 knockout models obliterated the inflammatory response from HA fragments but overall
have increased susceptibility to non-infectious tissue injury [70, 80]. TLR-2 and -4
knockout models lose the anti-inflammatory protective effect of HMWHA cell-surface
association [70]. HA fragments function to augment the immune-inflammatory cascade.

Native HA:
HMWHA is largely anti-inflammatory and evidence of its beneficial contribution to
wound healing is evident in patients with burns, venous stasis or diabetic ulcers [81]. A
rat model of inflammation also supports the anti-inflammatory effects of HMWHA.
Topical HMWHA (4 x 106 kDa) applied directly to the laminectomy site prior to wound
closure decreased the number of inflammatory cytokines and cells present during the
acute phase of wound healing [82]. HMWHA dampens the magnitude of an
inflammatory response by blocking the interaction of LMWHA with pro-inflammatory

21
receptors, inhibiting migration of white blood cells, and diluting the effect of
inflammatory cell mediators [30, 82]. Although HMWHA is anti-inflammatory in
experimental models, previous studies attempting to use topical HMWHA in the
prevention of radiation dermatitis have shown contradictory results in terms of effects on
inflammation [83-85]. Therefore further research is needed to clarify the relationship
between exogenous HMWHA and supporting its potential anti-inflammatory effects.

Proinflammatory Skin Disorders
Dysregulation of the immuno-inflammatory cascade, either from intrinsic or extrinsic
influences, can contribute to pro-inflammatory skin disorders [66]. For example,
unintentional increased levels of fragmented or LMWHA can support a proinflammatory
tissue state. In addition, any topically applied molecule has a theoretical risk of causing
either an allergic (ACD) or irritant contact dermatitis (ICD). Both ACD and ICD can
result from contact with non-protein chemical molecules, and the severity of the
cutaneous reaction depends on the characteristics of the contact itself and the robustness
of individual inflammatory responses [65]. Contact dermatitis are common family of
inflammatory skin diseases where damage to cutaneous integrity results in activation of
the innate immune system [65]. A non-specific pro-inflammatory reaction ensues with
hyper-production of cytokines such as IL-1α, IL-6, IL-8 and TNFα leading to apoptosis
of epidermal cells. Resolution usually occurs following elimination of the inciting
stimulus. In the development of new skin care products, it is important to consider the
likelihood of the product stimulating a local or systemic inflammatory reaction.
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Commercial topical hyaluronan applications
Biotechnology companies have capitalized using a plethora of HA applications to create a
niche market valued at over a billion dollars annually [86]. The skin industry represents
one of the primary stakeholders. Current commercial applications of HA aim to replace
endogenous HA with aging, augment tissue volume by exploiting the known hydrophilic
and anti-oxidant properties of HA, or as a component in wound dressings to promote
healing. Injectable HA fillers used in cosmetic dermatology usually require cross-linking
to improve stabilization and longevity. Overall, exogenous HA containing products have
tried to emulate the physiological microenvironment of youthful skin to optimize tissue
repair and rejuvenation.

HA can be produced from either animal or non-animal sources. The most common
animal derived HA is from rooster coombs [87]. Whereas, non-animal derived HA is
usually produced through a process of bacterial fermentation [52, 87]. HA has no species
specificity and is non-allergenic [87]. It is also semi-permanent and naturally degraded in
our skin. Thus, HA has a strong safety profile with few reported adverse outcomes.

It is well known that an intact SC is the primary barrier to topical administration of high
molecular weight hydrophilic molecules. Current HA technology has circumvented this
issue by using injectable formulations or topical penetration enhancers. Injectable crosslinked HA dermal fillers offer a painful and transient correction of volume, without
addressing the remaining physiologic deficits of aged skin. Pavicic et al. (2011) looked at
the effect of topical administration of HA creams of different molecular weights on
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periorbital wrinkles in women aged 30-60 [52]. Their group only showed an effect with
LMWHA (50-130 kDa), which they attributed to poor penetration of the HMWHA
groups [52] yet HMWHA is potentially a safer, more effective skin replacement since
homeostatic skin HA is largely in a native HMW form. Topical application of HMWHA
requires the use of penetration enhancers. Established penetration enhancers to aid the
delivery of HMWHA include chemical methods (e.g. DMSO), iontophoresis,
microneedles, and lipid nanoparticles/microemulsions [88]. However, the use of
penetration enhancers often leads to an unpredictable retention and activity of
exogenously applied HA [89]. A major problem with liposomes, nanoparticles and other
particulate enhancing formulations is that they are phagocytosed by cells and then HA is
rapidly destroyed in lysosomes. To date topical HA delivery modalities have failed to
reliably replenish native HMWHA in aged skin.

Identifying the problem
Native epidermal HMWHA is linked with a youthful skin phenotype. Replenishing
depleted HMWHA in the aged epidermis is optimal therapeutically but challenging as
HMWHA is highly hydrophilic and does not easily penetrate the lipophilic stratum
corneum (SC). Current penetration enhancers limit the retention or are rapidly destroyed
by skin cells of HA in the skin. In addition, the stability of exogenous HA depends on
interactions with HA receptors such as CD44, which show diminished expression with
aging [57, 62]. A more ideal formulation for topical HMWHA delivery would have
reliable penetration and retention in the skin and occur in a form that is not rapidly taken
up and destroyed by skin cells.
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HA-PE: a novel skin care technology
Hyaluronic acid phosphatidylethanolamine (HA-PE) is a patented technology
(WO2011/140630A1) developed in Dr. Turley’s lab. HA-PE is a modified hyaluronic
acid with approximately 6% of the disaccharide units of the native hyaluronan covalently
linked to phosphatidylethanolamine (PE). Phospholipids are the major components of the
plasma membrane and are therefore biocompatible molecules and are non-allergic [89].
In addition, phospholipids have the advantage of being amphiphilic [89]. Soy lecithin is a
heterogenous mixture of phospholipids, but most are neutral and do not react with HA.
PE is the most common phospholipid in lecithin. PE has both an amino and a carboxyl
group that can interact with the carboxyl group on the HA molecule. In the HA-PE
reaction

the

amide-linking

agent,

1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

(EDC), is also the limiting reagent and thus the ratio of EDC to HA ensure the
consistency of the formulation. After mixing HA-PE in a 1:1 (v/v) ratio with a
commercially available base cream, it is ready for topical application without the addition
of further penetration enhancing agents. Unlike the cross-linked HA of injectable fillers,
topical HA-PE transverses the skin barrier and forms pericellular coats mimicking
endogenous HA configurations. In addition, HA-PE is retained in skin independent of
HA receptors including CD44/RHAMM. HA-PE cream is a novel technology for topical
penetration of HMWHA.
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Figure 3. Schematic diagram of HA-PE molecular structure. Molecular structure of
HA is shown with attached phospholipid tail (shown in red).
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Chapter 2: Thesis Objectives and Aims
An in vivo study design using a murine model coupled with molecular analysis
techniques was used to assess the effects of a novel cream formulation, HA-PE. Once
daily, 0.18g of cream from one of three treatment arms (HA-PE, HA, or Vehicle Cream
alone) was applied to a shaved area on the back of retired breeder female mice. At three
time points (24 hours, 5 days, and 10 days) following the first cream application, five
mice from each treatment arm were sacrificed to harvest a full-thickness biopsy of the
treated skin and a blood sample. Using an aged murine model, this thesis examined the
effect of topical HA-PE cream on the epidermis using three primary objectives, which are
outlined below.

Topical HA-PE and the skin barrier
The addition of phosphatidylethanolamine groups to a high molecular weight (~ 500
kDa) hyaluronan will permit it to traverse the stratum corneum and be retained in the
keratinocytes of the epidermis as a pericellular coat following a single topical application.

Objective 1: To determine if HA-PE crosses the skin barrier following topical
application.
Aim 1: Following a single topical application of Alexa647 tagged HA-PE and HA,
harvest skin biopsies at 40 min, 2h, 4h, 8h, 24h, 48h, and 72h post application to
quantify the amount of fluorescence in the epidermis.
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Topical HA-PE and the epidermis

High-molecular weight hyaluronan in the epidermis exists primarily in the extracellular
matrix forming pericellular coats around keratinocytes. This configuration forms a fluid
scaffold that plays an important role in cell proliferation, differentiation, and signaling.

Objective 2: To characterize the effect of multiple applications of topical HA-PE on
the rejuvenation capacity of the epidermis.
Aim 1: Using hematoxylin and eosin stained skin specimens, quantify epidermal
thickness.
Aim 2: Using paraffin processed skin specimens, quantify the amount of staining
for immunohistochemistry markers of keratinocyte proliferation (Ki67) and
keratinocyte differentiation (K10) using image analysis software (ImageJ).

Topical HA-PE and Inflammation

High molecular weight hyaluronan can be degraded into proinflammatory low molecular
hyaluronan fragments. This thesis aims to examine the possibility of a proinflammatory
effect of topical HA-PE. Since localized inflammation manifests systemically, this was
examined at the site of topical application and in blood.

Objective 3: To determine if multiple topical HA-PE cream applications elicit either
a local and/or systemic response.
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Aim 1: Using paraffin processed skin specimens, quantify the amount of staining
of immunohistochemistry markers of activated Langerhans cells and macrophages
(F4/80) as a marker of local inflammation.
Aim 2: Identify the presence of an additional downstream marker of local
inflammation, TNFα, in tissue samples using an ELISA.
Aim 3: Examine systemic inflammation by comparing serum C-reactive protein
samples using an ELISA kit.
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Chapter 3: Methods
All experiments were approved by ethics and compliant with the standard operating
protocols of the Animal Use Subcommittee at the University of Western Ontario, Canada.
Topical cream formulation
HA-PE cream formulation:
For preparation of the HA-PE cream (CA Patent PCT/CIPO 2,703,532), 1.35 mL of
unrefined liquid soy lecithin (Soy Lecithin GT non-GM IP, Imperial-Oel-Import,
Germany) was mixed thoroughly at room temperature with 1.35 mL of 1% v/w Sodium
Hyaluronate Solution (500 kDa, Medical Grade, Lifecore Biomedical, Chaska, MN,
USA) and 252 µL of isopropanolol. Subsequently, 3.78 mg of dry 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) was added and mixed thoroughly as a linking
agent. After mixing for 10 – 15 minutes, 3 mL of vehicle cream was added and mixed for
another 5 minutes. A water-based cream (Mango Face cream, Aquatech, Toronto) used
throughout the study as the vehicle for mixing with unmodified HA or HA-PE. Creams
were stored protected from light at 4º C.

HA cream formulation:
For preparation of the HA cream, 1.35 mL of 1% v/w Sodium Hyaluronate Solution was
mixed thoroughly with 3 mL of vehicle cream. Creams were stored protected from light
at 4 º C.

30
Alexa647 mouse experiments
Preparation of Alexa647-HA:
In the preparation of Alexa647-HA, the solution was protected from ambient light. In a
laminar flow hood, 0.0028g of EDC (Sigma Aldrich) was dissolved in a 1 mL solution of
20 mM MES and 30% ethyl alcohol (pH 4.5) in a 15 mL tube. Subsequently, 200 uL of
pharmaceutical grade 1% v/w Sodium Hyaluronate Solution (500 kDa) (Lifecore
Biomedical, Chaska, MN, USA) was added. After five minutes, 300 uL of Alexa Fluor ®
647 Hydrazide, Tris (triethylammonium) salt (Life Technologies) was added.

The

Alexa647-HA solution was placed on a rocker at room temperature for 12 hours.

The Alexa647-HA solution was then injected into a Slide-A-Lyzer ® dialysis cassette
(10,000 MWCO, Thermoscientific) and placed in a 2 L dialysate of 1x PBS with a
stirring bar in a 4°C room. The entire volume of 1X PBS buffer was exchanged at 1, 3,
and 5 days. The Alexa647-HA solution was retrieved from the Slide-A-Lyzer ® and stored
in a 15 mL tube in the 4 °C fridge.

Animals:
Twelve retired breeder female C57BL/6 mice (The Jackson Laboratory) were used for the
Alexa647 mouse experiments. Older mouse skin is general defined as > 52 weeks of age
[56]. Animals were individually caged in a temperature-controlled breeding room with a
12h light/dark cycle, and fed a standard diet. The breeding room had low ambient light
exposure to prevent degradation of the fluorescent Alexa647 probe while awaiting harvest
of the tissue specimens.
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Treatment of Alexa647-HA/HA-PE mice:
Twelve retired breeder female C57BL/6 mice were used for the Alexa647 mouse
experiments. For the initial cream application, each mouse was anesthetized using
Isofluorane gas. While anesthetized, the upper dorsum of the back was shaven with an
electric razor, leaving a strip of hair in midline to define the right and left sides. The left
side was treated with Alexa647-HA cream and the right side was treated with Alexa647HA-PE cream. A total of 0.18 g of treatment cream was applied to the respective
treatment areas. Mice were individually caged and kept in the animal facility’s breeding
room to avoid high levels of ambient light exposure. Two mice were euthanized using a
CO2 chamber at each of six time points: 40 minutes, 2 hours, 4 hours, 8 hours, 24 hours,
and 72 hours following cream application.

Preparation of Alexa647 mouse tissue:
A full-thickness biopsy of the entire Alexa647-HA/HA-PE treated area was obtained and
lightly fixed for 10 minutes in a solution of 1.5% w/v paraformaldehyde (Sigma Aldirch)
and 0.5% w/v cetylpyridinium chloride monohydrate (Sigma Aldrich) in 1 x PBS. Each
specimen was fixed in 4% paraformaldehyde (pH 7.4) and stored at – 4 ° C, follow which
samples were paraffin embedded and sectioned at 10 µm thickness using a Microm HM
200 Ergostar Microtome (GMI; Ramsey, Minnesota, USA). A glass coverslip was
mounted on each slide using Prolong® Gold anti-fade reagent with DAPI
(LifeTechnologies).
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Analysis of Alexa647-HA-PE mice:
Ten images of each sample were taken per a mouse at 20X magnification using a Nikon
Eclipse motorized upright microscope (Nikon Canada Inc). Images were analyzed using
ImageJ 1.47). The pixel density per an area of epidermis using the Alexa647 channel was
averaged per a mouse.

Multiple daily topical cream application experiments
Animals:
Forty-five retired ten-month old female C57BL/6 mice (The Jackson Laboratory) were
used for the multiple cream application studies. Animals were individually caged in a
temperature-controlled environment with a 12 h light/dark cycle, and fed a standard diet.

Wounded mouse positive control for inflammation studies:
The inflammatory phase of wound repair in addition to acute and chronic models of
cutaneous inflammation share similar profiles of immune cells and chemical messengers.
For example, upregulated expression of TNFα, a pro-inflammatory cytokine, is observed
during the inflammatory phase of wound healing [74] in addition to acute and chronic
inflammatory skin disorders [72]. Activated macrophages known for their role in wound
healing, are also recognized as an important mediator in chronic inflammatory skin
disorders such as psoriasis [90]. Thus macrophages and pro-inflammatory cytokines,
such as TNFα, appear to be ubiquitous players in cutaneous inflammation regardless of
the inciting stimulus. A wounded mouse model was chosen as a positive control for the
local inflammation studies in this experiment.
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An additional wounded mouse was created as a positive control for the inflammatory
marker evaluations. This was a single ten-month old C57BL/6 mouse (The Jackson
Laboratory). After being anesthetized with Isofluorane gas, a 4 mm full-thickness skin
wound was created on the upper back of the mouse. The wounded mouse was caged
independently and stored in a temperature-controlled environment with a 12 h light/dark
cycle, and fed a standard diet. The wounded mouse was euthanized via a CO2 chamber 72
h post-wounding. The entire wounded area with a 2 mm perimeter of normal tissue was
excised. This area was divided into two parts: one half was kept for permanent sectioning
and the other half was stored at – 80 °C.

Treatment of multiple cream application mice:
At baseline, mice were divided into three sets of fifteen mice to define the three treatment
arms: HA-PE cream, HA cream, and vehicle cream. For the initial cream application,
each mouse was anesthetized using Isofluorane gas. While anesthetized, the upper
dorsum of the back was shaven with an electric razor and 0.18 g of treatment cream was
applied to the entire shaved area. Subsequent once daily cream applications were
performed without anesthesia. Groups of five mice in each treatment arm (HA-PE, HA,
and Vehicle cream) were sacrificed after one, five, and ten cream applications.

Animals were euthanized using a carbon dioxide chamber 24 h following the last cream
application. A blood sample from each mouse was obtained via a cardiac puncture
immediately following cessation of respiration. Subsequently, two four-millimeter punch
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biopsies were obtained. The remainder of the shaven treatment area was excised and
stored at – 80 °C.

Tissue preparation:
Tissue biopsies were fixed in a 4 % paraformaldehyde solution at 4 °C for 24 h. Samples
were then embedded in paraffin blocks and 4 µm sections were cut using a Microm HM
200 Ergostar Microtome (GMI; Ramsey, Minnesota, USA).

Effect of HA-PE on the epidermis
Epidermal Thickness Analysis:
To evaluate epidermal thickness, sections stained with hematoxylin and eosin were
uploaded to ImageJ 1.47 and analyzed at 4X magnification. For each mouse, fifty serial
measurements at 75 µm intervals per section were made to determine epidermal thickness
(stratum basale to the stratum granulosum).

Ki67 and K10 Immunohistochemistry:
Paraffin-embedded

sections

obtained

from

each

mouse

were

processed

for

immunohistochemical staining. Sections were deparaffinized in xylene and rehydrated in
a graded ethanol series. The sections were heated to a boil using a microwave oven in
0.01 M aqueous sodium citrate buffer (pH 6.0) for antigen retrieval. Following antigen
retrieval, the sections were washed in 1X PBS three times for 5 min each and treated with
3.0 % hydrogen peroxide for 10 min. Further washes with 1 x PBS were performed

35
before sections were blocked with 3.0 % bovine serum albumin for 1 hour at 4 °C. Then,
sections were incubated with diluted primary antibodies for 18-24h at 4 °C. The
following primary antibodies were used: rabbit Ki67 monoclonal (1:100 dilution; Abcam
ab16667) and rabbit K10 monoclonal (1:7000 dilution, Abcam ab76318). Following
washes, sections were incubated for 2 h at room temperature with biotinylated polyclonal
secondary antibodies (1:500 dilution, DAKO). Sections underwent further washes and
were reacted with streptavidin-horseradish peroxidase (1 in 2000 dilution, Abcam) for 30
min. Staining was visualized with diaminobenzidine (DAB) (2-component DAB kit;
DAKO). Sections were counterstained with hematoxylin and washed with distilled water.
A final ascending ethanol series and xylene wash were performed before cover slip
application using Richard-Allan Scientific Cytoseal 60 (ThermoScientific).

Keratinocyte Proliferation (Ki67) and Keratinocyte Differentiation (K10) Analysis:
Using Aperio© ImageScope (Aperio ePathology Solutions; http://www.aperio.com/) a
ruler measuring 500 µm increments was placed parallel to and above the epidermis of
each specimen. A total of two to three images per specimen were obtained at alternating
500 µm sections using 18.0X magnification. Specimens with significant ripping or
damage were excluded from analysis. The Aperio image was saved and transferred to
ImageJ 1.47. In the ImageJ 1.47 software, the epidermis area was traced along the 500
µm marked distance. The traced area was saved and isolated as a new image.

For the keratinocyte (Ki67) proliferation analysis, a total count of the basal keratinocyte
nuclei in the selected area was recorded. Subsequently, the new image was deconvoluted
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under the ‘H DAB’ setting. The deconvolution process allowed the software to separate
the different colour channels of the image to allow for isolation of the positive brown
staining from the Ki67 antibody. The deconvoluted image was set to a threshold pixel
range of 10-31 arbitrary units, to set a conservative assessment for identifying positively
stained cells. The number of positively stained nuclei was then recorded. The ratio of
positively stained nuclei to the total nuclei count was used to determine the percentage of
Ki67 staining per an area of epidermis.

For the keratinocyte (K10) differentiation analysis, an area measurement recorded in
pixels of the new image of 500 um of traced epidermis was obtained. The image was
deconvoluted under the ‘H DAB’ setting. The deconvoluted image was set to a threshold
pixel range of 10-60 arbitrary units, to set a conservative estimate for identifying
positively stained cells. Using the Histogram analysis tool, a pixel count of the amount of
positive K10 staining was recorded. The ratio of the number of pixels of K10 staining to
the total area pixels was used to determine the percentage of K10 staining per area of
epidermis.

For both Ki67 and K10, five images analyses were performed and averaged per an
individual mouse. Pooled average data was then calculated per treatment arm (HA-PE,
HA, and Vehicle) and time point (1 day, 5 days, 10 days).

37
Effect of HA-PE on inflammatory markers
F4/80 Immunohistochemistry:
The immunohistochemistry protocol was identical as previously described. The primary
used in this series was a rat F4/80 monoclonal antibody (1:100 dilution, AbD Serotec).
F4/80 antibody is used to detect a surface marker present on mature mouse macrophages.

F4/80 Analysis:
Aperio© ImageScope (Aperio ePathology Solutions; http://www.aperio.com/) was used
to obtain images of F4/80 slides at 20X magnification. Specimens with significant
ripping or damage were excluded from analysis. The Aperio images were saved and
transferred to ImageJ 1.47. Using ImageJ, the area of the entire dermis and subcutaneous
tissue was traced for each specimen. Subsequently, the number of F4/80 positively
stained cells within this area were recorded. The wounded mouse specimen was used as a
positive control for this experiment.

The number of F4/80 positive cells per area was expressed as a percentage of the number
of F4/80 positively stained cells in the wounded mouse positive control. Seven to ten
specimens were analyzed per a mouse.

TNF-α ELISA Methods:
Protein Isolation
Individual dissected tissue samples from each of the day 10 multiple application trial
mice were mixed gently with 300 uL of RIPA lysis buffer and a protease inhibitor tablet
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(Roche) for 10 minutes. An additional tissue sample from the wounded C57BL/6 mouse
was prepared as a positive control. Subsequently, each sample was lysed further using a
sonicator for three 20-second pulses. Samples were put on a shaker in the 4 º C cold room
for an additional 45 minutes. Subsequently, samples were centrifuged at 4 º C for 30
minutes at 13 000g. The resultant supernatant from each sample was transferred to a new
eppendorf tube, and the pellet was discarded.

TNF-α ELISA protocol
A TNF-α mouse ELISA kit (Abcam (ab100747)) was used as per the manufacturers
instructions to evaluate the presence of TNF-α in the experimental samples and wounded
mouse positive control sample. Triplicates of 100 uL of each sample supernatant were
used. The absorbance of each set of triplicates was read at 450 nm using a Wallace
Victor2 1420 Multilabel Counter and Manager software (v 3.00.0.53, © 1997-2005
Perkin Elmer).

The average zero standard sample absorbance was subtracted from the average
absorbance of each triplicate repeat. The final value for each mouse was then evaluated
as a percentage of the average absorbance of the wounded mouse positive control.

C-Reactive Protein ELISA Methods:
Sample Preparation
Serum obtained via cardiac puncture at the time of euthanasia was collected in a sodium
heparin coated vacutainer tube (BD, Franklin Lakes, NJ, USA). Within one hour of

39
collection, the serum samples were centrifuged at 3000 rpm at 4 °C for 10 minutes using
an Eppendorf Centrifuge 5810R 15amp version. The supernatant was transferred to
individual labeled containers and stored at – 80 °C until analysis.

C-Reactive Protein (CRP) ELISA Protocol
A C-reactive protein mouse ELISA kit (Abcam (ab157712)) was used as per the
manufacturers instructions to quantify the presence of serum CRP in the experimental
samples. Triplicates of 100 uL of each sample supernatant and standards were used. The
absorbance of each set of triplicates was read at 450 nm using a Wallace Victor2 1420
Multilabel Counter and Manager software (v 3.00.0.53, © 1997-2005 Perkin Elmer).

The final serum CRP concentration (ng/mL) for each mouse was calculated using the
slope of the curve (absorbance versus concentration) generated for the standard samples
provided by the manufacturer.

Statistical Analysis
Parametric evaluations, including Student’s T Test and OneWay ANOVA, were used to
determine statistical significance between groups using a p value of 0.05. Tukey’s posthoc analysis was used to identify which groups exhibited a statistically significant
difference. Data are expressed as mean ± standard error of the mean (SEM) of at least
five independent samples as described above. Statistical analysis was performed using
GraphPad Prism 6 (GraphPad software).
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ABSTRACT
Aged keratinocytes have diminished proliferative capacity and hyaluronan (HA)
cell coats, which are losses that contribute to atrophic skin characterized by reduced
barrier

and

repair

functions.

We

formulated

HA-phospholipid

(phosphatidylethanolamine, HA- PE) polymers that form pericellular coats around
cultured dermal fibroblasts independently of CD44 or RHAMM display. We
investigated the ability of these HA-PE polymers to penetrate into aged mouse skin
and restore epidermal function in vivo. Topically applied Alexa647-HA-PE penetrated
into the epidermis and dermis, where it associated with both keratinocytes and
fibroblasts. In contrast, Alexa647-HA was largely retained in the outer cornified layer
of the epidermis and quantification of fluorescence confirmed that significantly more
Alexa647-HA-PE penetrated into and was retained within the epidermis than Alexa647HA. Multiple topical applications of HA-PE to shaved mouse skin significantly
stimulated basal keratinocyte proliferation and epidermal thickness compared to HA
or vehicle cream alone. HA-PE had no detectable effect on keratinocyte differentiation
and did not promote local or systemic inflammation. These effects of HA-PE polymers
are similar to those reported for endogenous epidermal HA in youthful skin and show
that topical application of HA-PE polymers can restore some of the impaired functions
of aged epidermis.

KEYWORDS:

hyaluronan, hyaluronan-phosphatidylethanolamine, pericellular coats,

keratinocyte, proliferation
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INTRODUCTION
Hyaluronan (HA) is an ubiquitous extracellular matrix tissue polysaccharide belonging
to the glycosaminoglycan family, which are characterized by repeating hexosamines
and uronic acid [1-3]. Skin HA accounts for approximately 50% of total body HA and
occurs in both the epidermal and dermal layers. Here it performs a variety of functions
that are related to its rheological, viscoelastic and biological properties[4-6]. For
example, its rheological properties contribute to the overall quality, hydration,
permeability and immune barrier functions of skin while its unique viscoelastic
properties protect skin cells from mechanical damage [7-11]. The biological properties
of HA include a contribution to cell survival, proliferation and migration, and result
from its ability to activate key signaling cascades through interactions with cellular
HA receptors, which in keratinocytes is primarily CD44 [12-18]. HA is also an
important regulator of skin immune surveillance [19] and response to injury
processes [15, 20-25]. Although the primary structure of HA is simple and
composed only of linear repeating N-acetyl-D- glucosamine and glucuronic acid
disaccharides, its functions are complexly regulated and dependent

upon

its

organization by extracellular and cellular proteins as well as by polymer size [14,
16, 21, 23].

The organization of HA in the extracellular matrix and around cells is a critical
component of its skin functions [6, 26, 27]. On keratinocytes, HA is structured as
compact pericellular coats that are maintained by CD44. Dermal HA is more
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abundantly extracellular and linked to a variety of proteoglycans including versican
[28-34]. The cellular and extracellular organization of skin HA is critical for its
retention in the papillary dermal and keratinocyte layers. Quantitative loss of HA
from these layers is associated with skin pathologies including poor wound healing,
reduced skin elasticity/mobility, and loss of keratinocyte tight-junctions and
permeability barrier functions [27, 29, 35-45]. Polymer size also contributes to the skin
functions of HA. For example high molecular weight (HMW), native HA in skin
protects against tumor initiation [46], provides intrinsic water binding properties of
skin [26] and is required for dendritic cell functions [15, 19, 47]. It regulates the
proliferation and differentiation of the basal keratinocyte layer during homeostasis and
response to injury [4, 6, 48, 49], and contributes to the barrier/hydration function [26,
34, 50] and structure of the stratum corneum [51].

Most HA in homeostatic skin is high molecular weight but fragmentation occurs
following injury or prolonged exposure to UV. In cooperation with the fragmentation
of other extracellular matrix components, HA fragments activate signaling cascades in
keratinocytes and dermal fibroblasts that control migration, survival and redifferentiation required for repair of injured skin [52-59]. HA fragments are also key
regulators of innate immunity and are required for in-trafficking and pro-inflammatory
cytokine expression of macrophages [15, 19]. The different functional effects of native
versus fragmented HA likely result from selective interactions with specific receptors
and differential effects of polymer size on the clustering/signal activation through these
receptors [13, 15, 60]. The effects of native HA on homeostatic keratinocyte functions
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are mediated through CD44 [30, 38] while repair functions of HA fragments involve
coordination of signaling through CD44: RHAMM and TLR2, 4 complexes [56, 61, 62].

Chronological skin aging results in physiological alterations of keratinocytes and
epidermal functions that contribute to epidermal thinning or atrophy, barrier
dysfunction, delayed wound repair, as well as increased susceptibility to pathologies
including ulceration, dermatitis and eczema [4, 61, 63]. Although age-associated
epidermal dysfunction is not well understood, it is associated with changes in HA
concentration and organization, and CD44 display [38, 64]. Experimental models
have established that reduction or loss of keratinocyte CD44 results in epidermal
changes that are similar to aging dysfunction such as thinning of the epidermal layer,
barrier dysfunction, modified HA metabolism, reduced HA production, altered
keratinocyte differentiation and decreased skin elasticity. Application of HA to
aged mouse skin partially restores permeability barrier homeostasis and epidermal
thickness [42, 43]. Topical or injected HMW HA products have had variable effects
in restoring a sustained physiological and hydrated microenvironment of youthful
skin required for optimizing tissue repair and rejuvenation [38, 63, 65, 66]. Transepidermal or dermal HA delivery modalities, although promising, have similarly
failed to reliably replenish sustained high levels of native HMW HA in the epidermis
or dermis of aged skin [67-69]. This failure is likely because of poor penetration of
topically applied HA formulations of MW greater than 50 KDa [40, 70-72], reduced
HA capture in the epidermis as a result of declining CD44 levels [38, 43, 73] and
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aberrant organization as well as rapid clearance of the exogenous HA formulations [41,
61].

To address this problem, we developed a cell-based screening method for
identifying HA-phospholipid (phosphatidylethanolamine, HA-PE) formulations that
form pericellular HA coats on fibroblasts and keratinocytes in a CD44-independent
manner [74]. We show that topical administration of HA-PE to the shaved skin of
aged wild type or CD44-/- mice increased HA within the epidermal layer. This HA
modification promoted basal keratinocyte and hair follicle proliferation as well as
increased epidermal thickness but does not detectably alter the differentiation of
keratinocytes. In addition, topical application of HA-PE in vivo did not result in either
a local or systemic inflammatory response.

METHODS
Animals:
Forty-five

retired

breeder

ten-month

old

female

C57BL/6

mice

(Jackson

Laboratory) were used for the multiple cream application studies. An additional twelve
retired breeder twelve-month old female C57BL/6 mice were used for the Alexa647
mouse experiments.

Animals were individually caged in a temperature-controlled environment with a
12h light/dark cycle, and fed a standard mouse chow diet. All experiments were
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approved by and compliant with the standard operating protocols of the Animal Use
Subcommittee at the University of Western Ontario, Canada (2009-051).

Preparation of HA-PE and HA:
For preparation of the HA-PE cream (Patent identification: WO2011140630 A1)[75],
1.35 mL of unrefined liquid soy lecithin (Soy Lecithin GT non-GM IP, Imperial-OelImport, Germany) was mixed thoroughly at room temperature with 1.35 mL of 1% v/w
Sodium Hyaluronate Solution (500 kDa, Medical Grade, Lifecore Biomedical, Chaska,
MN, USA) and 252 µL of isopropanolol. Subsequently, 3.78 mg of dry 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) was added and mixed thoroughly as a linking
agent. After mixing for 10 – 15 minutes, 3 mL of vehicle cream was added and mixed for
another 5 minutes. For preparation of unmodified HA cream, 1.35 mL of 1% v/w Sodium
Hyaluronate Solution was mixed thoroughly with 3 mL of vehicle cream.

A water-based cream (Mango Face cream, Aquatech, Toronto) was used throughout
the study as the vehicle for mixing with unmodified HA or HA-PE. Formulated creams
were stored protected from light at 4º C.

HA pericellular coat detection:
HA pericellular coats were detected using particle exclusion [76]. Dermal wild type,
CD44-/-, RHAMM-/- and CD44:RHAMM-/- embryonic fibroblasts were plated onto
35 mm tissue culture dishes in DMEM + 10% FBS for 24 hrs. Cells were then fixed in
2.5% glutaraldehyde in 0.1 M cacodylate buffer, 5 mM CaCl2, pH 7.2, for 30 min then
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washed gently in Cacodylate buffer. 1 ml of either FITC-labeled 0.4 mm
microspheres (Invitrogen) or formalized sheep erythrocytes (1X108 erythrocytes/ml)
were added to each 35 mm culture dish and swirled gently so that cells were evenly
covered. Dishes were incubated for 15-30 min at 37 oC to let beads or erythrocytes
settle around cells.

As a control, cells were incubated with 200 µg/ml bovine

testicular hyaluronidase (Sigma) for 1 h at 37 oC prior to performing the particle
exclusion assay. Cells were then photographed with a Nikon inverted microscope
equipped with epifluorescence and Hoffmann optics.

Preparation of Alexa647-HA:
In the preparation of Alexa647-HA, the solution was protected from ambient light. In a
laminar flow hood, 0.0028 g of EDC (Sigma Aldrich, http://www.sigmaaldrich.com) was
dissolved in a 1 mL solution of 20 mM MES and 30% ethyl alcohol (pH 4.5) in a 15 mL
tube. Subsequently, 200 uL of pharmaceutical grade 1% v/w Sodium Hyaluronate
Solution (500 kDa) (Lifecore Biomedical, Chaska, MN, USA) was added. After five
minutes, 300 uL of Alexa Fluor ® 647 Hydrazide, Tris (triethylammonium) salt (Life
Technologies, http://www.lifetechnologies.com) was added. The Alexa647-HA solution
was placed on a rocker at room temperature for 12 hours then dialyzed (10,000 dalton cut
off, Thermoscientific) at 4 °C. The entire volume of 1X PBS buffer was exchanged at 1,
3, and 5 days. The retained Alexa647-HA solution was retrieved from the dialysis
apparatus and stored in a 15 mL tube in the 4 °C fridge.
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Application of Alexa647-HA/HA-PE to mice:
Mice were anesthetized using Isofluorane gas for application of cream. While
anesthetized, the upper dorsum of the back was shaved with an electric razor, leaving
a strip of hair in midline to define the right and left sides. 0.18 g of Alexa647-HA
and Alexa647-HA-PE cream was applied to the left and right sides respectively. Two
mice were euthanized using a CO2 chamber at each of six time points: 40 min, 2 h, 4 h,
8 h, 24 h, and 72 h following cream application.

Preparation and analysis of Alexa647-HA-PE:
A full-thickness biopsy of the Alexa647-HA/HA-PE treated area was obtained and
lightly fixed for 10 minutes in 1.5 % paraformaldehyde containing 0.5 %
cetylpyridinium chloride monohydrate [76] in PBS. Each specimen was subsequently
fixed in 4 % paraformaldehyde (pH 7.4) for an additional 30 min then stored at – 4
° C. Tissue samples were paraffin processed, mounted then analyzed with a Nikon
Eclipse motorized upright microscope. The penetration of Alexa647-HA/HA-PE into
the epidermis was quantified using ImageJ, which converted fluorescent images to
pixel density per a tissue area. A total of twelve C57BL/6 retired breeder female mice
were used for this experiment.

Treatment of mice with HA-PE:
Three treatment arms were used for these experiments: HA-PE cream, HA cream,
and vehicle cream and 15 mice were used/group. For the initial cream application mice
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were anesthetized, shaved and treated as described above. Subsequent once daily cream
applications were performed without anesthesia. Five mice in each treatment arm
were sacrificed after one, five, and ten applications. At each of these times, mice were
euthanized, a blood sample via a cardiac puncture and two four-millimeter punch
skin biopsies were obtained. The remainder of the shaven treatment area was
excised and stored at – 80 °C. To provide a positive control for inflammation markers,
an additional mouse was wounded with a 4 mm punch biopsy as described previously
[77], then tissue harvested using an 8 mm punch biopsy 3 days after wounding. All
tissue biopsies were fixed in 4 % paraformaldehyde/PBS at 4 °C for 24 h. Samples
were then processed for paraffin histology sections. For immunohistochemistry, tissue
sections were deparaffinized and antigen retrieval performed by heating tissue sections
in a microwave oven in 0.01 M aqueous sodium citrate buffer (pH 6.0). Tissue sections
were washed then incubated with one of the following primary antibodies: rabbit Ki67
monoclonal (1:100 Abcam), rabbit K10 monoclonal (1:7000 dilution, Abcam), and
rat F4/80 monoclonal (1:100 dilution, AbD Serotec) followed by the appropriate
biotinylated secondary antibody. Sections were counterstained with hematoxylin then
mounted in Richard-Allan Scientific Cytoseal 60 (ThermoScientific). Digital images of
stained tissue sections were obtained using an Aperio Scanscope. Five representative
areas were taken per mouse and analyzed using ImageJ.

Measurement of Epidermal Thickness:
To evaluate epidermal thickness, the above tissue sections stained with hematoxylin
and eosin (4X magnification images) were analyzed using Image J. For each mouse,
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fifty serial measurements at 75 um intervals per section were made to determine
epidermal thickness (stratum basale to the stratum granulosum) [78].

TNF-α ELISA:
Activated macrophages and proinflammatory cytokines, such as TNFα, appear to
be ubiquitous players in cutaneous inflammation regardless of the inciting stimulus
whether wounding or sterile inflammation [79-81]. Dissected tissue samples from
each of treatment and group and wounded tissue were mixed gently RIPA lysis
buffer and a protease inhibitor tablet for 10 min then sonicated for three 20-second
pulses. Samples were incubated on a rotary shaker at 4 º C in lysis buffer for an
additional 45 min then centrifuged at 13,000 g (4 ºC) for 30 min. The pellet was
discarded and supernatant used for the TNFα-ELISA assays (Abcam), which were
performed per the manufacturers instructions. Triplicate samples of 100 uL of each
were used for these assays.

C-Reactive Protein ELISA:
Serum was obtained from blood harvested via cardiac puncture. The serum samples
were centrifuged at 3000 rpm at 4 °C for 10 mins using an Eppendorf Centrifuge and
stored at – 80 °C until analysis. Samples were analyzed for the presence of CReactive protein using an ELISA kit (Abcam) and assays were performed using the
manufacturers instructions. Triplicates samples (100 uL) of each sample were used for
these assays.
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Statistical Analysis:
OneWay ANOVA and Tukey test, as a post-hoc analysis, were used to determine
statistical significance between groups using a p value of 0.05. Data are expressed
as mean ± standard error of the mean (SEM) of at least five independent samples
as described above. Statistical analysis was performed using GraphPad Prism 6
(GraphPad software).

RESULTS
A. Formulating and characterizing HA-PE polymers that forms pericellular coats
Using a cell-based screen, HA-PE polymer formulations were prepared. The polymer
formulations that formed nanoparticles were discarded while those that were nonparticulate and formed pericellular coats on fibroblasts were identified using particle
exclusion assays (Figure 1A). Addition of HA-PE polymer resulted in a significant
increase in the number of cells that formed pericellular coats compared to those formed
when PBS alone was added. A light but significant increase in the number of cells
forming coats was also stimulated by exogenous unmodified HA of the same size used
for HA-PE formulations. Nevertheless, the addition of HA-PE stimulated coat formation
to a significantly greater extent than HA alone and a trend to formation of larger coats
was also observed (data not shown).
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CD44 has been demonstrated to be critical for keratinocyte, fibroblast and smooth
muscle cell HA coat formation [32-34, 41, 43] and both CD44 and RHAMM [12, 14,
62] have recently been implicated in the binding of HA to tumor cells and fibroblasts.
The role of these HA receptors in the formation of endogenous HA and HA-PE coats
was examined by comparing wild type primary mouse embryonic fibroblasts (MEF)
with those lacking RHAMM, CD44 or both receptors due to genetic deletion of these
genes (Figure 2A). Loss of RHAMM resulted in highly variable numbers of MEF
forming endogenous pericellular coats but these were not significantly different from
wild type fibroblasts. Loss of CD44 however resulted in a 6-fold reduction in the
number of MEF exhibiting HA coats. Dual loss of CD44 and RHAMM did not
further reduce coat loss from that observed in CD44-/- MEF. These results show that
CD44 is the major HA receptor that facilitates endogenous HA coat formation in
MEF consistent with previous studies of other cell types including keratinocytes [33,
40, 43]. The effect of HA-PE on RHAMM-/-, CD44-/-, RHAMM: CD44-/- and wild
type MEF coat formation was compared next to begin to identify the mechanisms for
HA-PE-promoted pericellular HA coats. As shown in Figure 2B, the addition of HA-PE
to these different fibroblast genotypes resulted in a similar number of cells with HA
coats indicating that HA-PE effects were not dependent upon HA receptor display
including CD44, which has previously been shown to mediate endogenous coat
formation (Figure 2 B, C). However, HA-PE stimulated coat formation in CD44-/MEF was sensitive to hyaluronidase as were endogenous coats (Figure 2C). These
results predict that addition of a PE group to HA promote its direct association with
cells in a CD44-independent manner.
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To determine if HA-PE promotes coat formation in other cell types particularly in
vivo, its effect on skin keratinocyte HA pericellular coats, which have previously been
shown to require CD44 expression [30, 43] was next evaluated. Adult mouse back
skin was chosen for these studies since it has been reported to produce very little
endogenous HA [29], permitting more sensitive detection of exogenous applications
of HA-PE using staining methods to detect accumulated HA. Consistent with previous
studies [29], very little HA staining was observed in control (PBS) keratinocytes.
Topical application of HA-PE to wild type mice significantly increased HA staining in
the epidermis (Figure 3) but did not detectably increase HA staining in the dermis when
compared to PBS-treated controls likely because the dermis produces large amounts of
HA and the staining method was not sensitive enough to detect elevation above this
high background. These results show that HA-PE not only enhances pericellular HA
coat formation in cultured MEF but also in epidermal keratinocytes in vivo. These
results also show that HA-PE crosses the outer cornified epidermal layer more
efficiently than unmodified HA.

The association of HA with keratinocytes in mouse skin in vivo depends upon
CD44 expression [30]. We therefore next assessed if the loss of CD44 altered HA-PE
mediated increases in keratinocyte associated HA in vivo. As shown in Figure 3B,
topical application of HA-PE increased hyaluronan staining of CD44-/- epidermis
compared to PBS controls suggesting that epidermal accumulation of HA-PE is CD44
independent in vivo similar to cultured MEF. To more directly follow the association of
small amounts of HA-PE with the epidermal and dermal skin layers, we labeled HA-PE
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with Alexa-dye and analyzed its distribution after a single topical application to mouse
skin.

B. Alexa647-HA-PE accumulates in the epidermis and penetrates into the dermal
and sub-dermal skin layers.
Alexa647-HA-was prepared, linked to PE (A647-HA-PE) or not (A647-HA) and applied
as equal amounts of HA to the shaved back skin of mice as described in methods.
Skin biopsy samples were collected from 40 min to 72 h after the single application,
processed for histology and examined with a confocal microscope. Confocal images
showed accumulation of A647-HA-PE and particularly A647-HA on the stratum corneum
but A647- HA-PE also penetrated into the stratum granulosum as well as the basal
keratinocyte layers (Figure 4). Fluorescence was also observed in dermal fibroblasts
and even within the subcutaneous muscle layer. Further analysis of the epidermis
revealed that A647-HA- PE was most strongly associated with subpopulations of basal
keratinocytes, and formed coats around these cells (Figure 4, arrows). A647-HA-PE also
was detected in fibroblasts of the upper dermis. In contrast, A647-HA primarily
accumulated in the outer stratum corneum with much smaller amounts penetrating
into the epidermis and dermis. In particular, A647-HA accumulation was not
concentrated in the basal layer (Figure 4).

Since the boundary of the epidermal layer is clearly identified, the amount of A647HA- PE in this layer was quantified using image analysis as described in methods. For
these analyses, the fluorescent intensity of Alexa647 HA, Alexa647HA-PE and a negative
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control vehicle cream were compared from the stratum basale to stratum granulosum
layers of the epidermis. A647-HA-PE penetrated into the epidermis as early as 40
min after application and could be detected up to 72 h after application (Figure 4).
Accumulation of A647-HA-PE in skin was significantly greater than A647-HA at all
time points but reached a maximum difference of 5 fold at 2 h. This significantly
elevated accumulation of A647-HA-PE versus A647-HA was sustained for 24 h
suggesting that HA-PE was able to establish a stable organization within the
epidermis. Although A-647-HA-PE levels were still greater than A-647-HA at 72 h
after application, the difference did not reach statistical significance (Figure 4).

Confocal analysis (24 h shown, Figure 4) showed that A647-HA primarily accumulated
in the outer stratum corneum with little penetration into the dermis. A647-HA-PE was
also present in the stratum corneum but unlike unmodified A647-HA, accumulated
around dermal fibroblasts. These results show that HA-PE readily penetrates into and is
retained in the epidermal and deeper skin layers

The formation of pericellular HA coats have been linked to cellular detachment
during mitotic rounding of proliferating fibroblasts and smooth muscle cells[12, 16,
82]. HA coats have also been linked to migration and differentiation of keratinocytes
in organotypic cultures[13, 14, 30, 38, 83, 84]. We therefore next assessed if
increasing keratinocyte HA coat formation by application of HA-PE affects the
proliferation or differentiation of this skin cell type.
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C. HA-PE increases epidermis thickness and basal keratinocyte proliferation but
does not affect keratinocyte differentiation or dermal cell proliferation.
The consequence of repeated HA-PE topical application on epidermal thickness was
first quantified. As shown in Figure 5, daily topical application of HA-PE
significantly enhanced epidermal thickness by 24 h, 5 days and 10 days after treatment
initiation when compared to application of unmodified HA or vehicle control.
Maximal epidermal thickness occurred between 24 h and 5 days and was sustained
throughout the treatment period (Figure 5). The tissue samples were dehydrated
prior to analysis of epidermal thickness, therefore did not account for
any in vivo contribution of increased tissue hydration from hyaluronan.

Consistent with this thickening effect on the epidermal layer, topical application of
HA-PE stimulated basal keratinocyte proliferation compared to unmodified HA or
vehicle controls as detected by Ki67 staining, which is a cell proliferation marker. In
addition, increased Ki67 staining of the suprabasal keratinocytes was observed in the
HA-PE group. The majority of epidermal proliferation and regeneration occurs by
activation of stem cells in the basal layer of the epidermis. The suprabasal levels contain
transit-amplifying (TA) intermediate stem cells which are defined by a finite number of
cell divisions before entering a terminal differentiation pathway (85). The HA-PE cream
appears to stimulate both the basal layer stem cells in addition to the TA stem
cells. Increased keratinocyte proliferation was observed 1 day after treatment initiation
and was sustained throughout the treatment period, corresponding well with the time
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frame observed for the increase in epidermal thickness (Figure 6). Analysis of DAPIstained skin sections 24 and 72 h after application of HA-PE or HA showed that dermal
cell number was similar in both treatments suggesting that HA-PE does not stimulate
fibroblast or other dermal cell proliferation.

This predicts that HA-PE effects on

proliferation are limited to the epidermal layer.

Growth

factors

such

as

keratinocyte

growth

factor

(KGF)

that

promote

keratinocyte proliferation coincidentally inhibit keratinocyte differentiation and
hyaluronan production [86, 87]. We therefore next assessed if elevating HA around
keratinocytes affects their differentiation cycle. The consequence of HA-PE
application on the expression

of

keratin-10

(K-10)

was

quantified

using

immunohistochemistry. No detectable effect of HA-PE application on K-10 staining
was observed suggesting that HA-PE does not modify keratinocyte differentiation
(Figure 7).

D. Topical application of HA-PE does not affect local skin or systemic inflammation.
Since HA and its fragments are potent regulators of the immune system in particular
innate immunity [15, 19, 47, 88], which could indirectly affect keratinocyte
proliferation, we next determined if topical application of HA-PE affected local or
systemic inflammation. F4/80 staining of skin tissue sections and TNFα was used to
identify localized activation of macrophages while serum CRP levels were monitored
to determine effects on systemic inflammation. As shown in Figure 9, the application
of HA-PE did not increase F4/80 staining levels compared to unmodified HA or
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vehicle controls. Furthermore, the levels of macrophage activation detected by this
method were very low compared to those detected in skin wounds, which are known to
contain high levels of activated macrophages [89] and were used as a positive control.
Similarly local TNFα and systemic CRP inflammation levels were not increased by
topical application of HA-PE compared to unmodified HA or vehicle controls (Figure 8
A, B).

DISCUSSION
Our results identify a method for preparing HA-phospholipid (PE) polymers that do
not require CD44 display for forming pericellular coats around fibroblasts in culture and
aged keratinocytes in wild type and CD44-/- mice. These results are consistent with a
mechanism whereby HA-PE inserts directly into the cell membrane via the
phospholipid entity. The topical applications of this HA-PE polymer increased
epidermal thickness of aged female mouse skin as a result of stimulating the
proliferation of the basal keratinocyte layer in the absence of detectable dermal or
systemic inflammation or changes in keratinocyte differentiation rates.

Topical application of unmodified HA to intact skin in situ penetrated into the epidermis
and dermis as previously reported [43, 70-72] but this was limited compared to HAPE polymers. In addition, most of the unmodified HA remained associated with the
stratum corneum and was not retained in skin as long as HA-PE. The ability of
unmodified HA to penetrate the skin in small amounts, which can occur in both rodent
and human skin, is dependent upon molecular weight. Thus, HA polymers smaller
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than 50,000 Da readily penetrate human skin ex vivo while larger HA chains do not
[70]. The average MW of HA used in the present study was 500,000 Da and therefore
the limited association of unmodified HA with the epidermis is likely due to the
polymer size restriction. The penetration of this HA size through the outer stratum
corneum is facilitated by the additional of a phospholipid moiety and this addition
likely increases solubility of HA in lipids (e.g. ceramides, cholesterol and fatty acids)
[90] that are present in the stratum corneum. Retention within the epidermis and dermis
is likely promoted by the ability of keratinocytes and fibroblasts to capture and retain
HA-PE as demonstrated in culture. Since HA-PE is able to organize as a pericellular coat
in the absence of CD44 display, HA-PE polymers are able to spontaneously organize
within the epidermis and we predict that keratinocyte CD44 acts at least in part as an
anchor for attaching HA to outside of cells.

Dermal and epidermal homeostasis is compromised in aging and a variety of
disease processes. Aged skin is characterized as dry, atrophic, inelastic, and wrinkled.
The key molecule required for water retention within skin is HA. Both the amounts
and organization of HA change in skin with intrinsic (chronological) and extrinsic
(photodamage) aging [4, 91, 92]. With chronological aging while HA is retained
within the aged dermis, it is precipitously lost from the epidermis. HA retained within
the aged dermis is however modified in its organization and this change together with
epidermal loss are thought to contribute to some of the above malfunctions of
aged skin [38]. Additionally, expression of skin HA receptors including CD44 are
increasingly reduced with age. Even though intrinsic and extrinsic skin aging are
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distinctive processes, they share similarities in molecular mechanisms. For example,
extrinsic causes of premature aging such as chronic exposure to UV also results in
loss of skin moisture, HA and HA receptor expression. Importantly, photoaging is also
associated with a decrease in the size of HA that will likely affect its ability to
organize into structures such as pericellular coats [73]. HA performs a variety of
functions in skin and this age dependent loss is considered to impact upon skin
moisture, barrier functions, epidermal thinning and sluggish response to injury [34].
The ability of HA-PE polymers to increase rodent epidermal thickness and
epidermal proliferation predict that this formulation has the potential for reversing
some of the intrinsic and extrinsic age-related epidermal defects such as epidermal
thinning and reduced repair response [93-95].

Our results showing that HA-PE promotes epidermal thickening and keratinocyte
proliferation are similar to the ability of exogenous high molecular weight HA to
affect functions of aged keratinocytes in culture and in vivo [33, 35, 40, 43]
although in the present study topical HA-PE had a significantly greater effect than
unmodified HA. Our data suggest that this results from increased basal keratinocyte
proliferation rather than enhanced differentiation. Previous reports have similarly
noted an increase in keratinocyte proliferation in response to topical HA but noted this
effect was maximal for intermediate (50,000-400,000 Daltons) and no effect was noted
for large HA (>400,000 Daltons) [40]. In another study, topical application of large HA
promoted epidermal barrier function and keratinocyte differentiation [43]. The
different effects of high versus intermediate HA fragments in these studies may have
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been due to the documented poor penetration of high molecular weight HA [70] that
is confirmed here. The ability of 500,000 Da HA-PE to promote keratinocyte
proliferation is likely because it efficiently penetrated to and was retained in the basal
keratinocyte layer to a much greater extent than unmodified HA.

A number of topical HA formulations have been developed in the past decade most
of which are composed of intermediate-small HA fragments (e.g. < 50,000 Da) or nanoparticulate formulations [4, 96]. Although these have shown efficacy (e.g. [97]) in
terms of treating skin disorders, we pose that HA-PE formulations will be more
effective since they are designed to replace the naturally occurring HA pericellular coat
that is depleted during aging and other conditions that cause epidermal atrophy [35,
40], and will also therefore be retained within the epidermis for longer times.
Particulate formulations by their nature tend to stimulate endocytosis and such
formulations are rapidly depleted from tissues [98-100]. Topical application of
intermediate unmodified HA has the advantage of being non-particulate and able to
penetrate skin readily but is dependent upon the expression of keratinocyte CD44 for
effects on keratinocyte function, which is depleted with age-related or other causes of
epidermal atrophy.

The consequences of exogenous HA or inhibition of endogenous HA show that
CD44 mediates the consequences of HA on keratinocyte function [6, 38, 61, 85]. For
example, the effects of topical HA on keratinocyte differentiation and proliferation
are ablated when CD44 function is blocked or expression is lost [35, 40, 43].
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CD44 appears to regulate multiple downstream signaling pathways to control these
keratinocyte processes and these include coordination of signaling through EGFR,
activation of RHO GTPase and translocation of activated ERK1,2 to the cell
nucleus [17, 35, 38, 85, 101]. The mechanisms by which HA-PE control basal
keratinocyte proliferation and the dependence of this effect on CD44 expression are
currently being investigated.
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Manuscript: Figure 1. HA-PE simulates pericellular coat formation in cultured
fibroblasts. 500 kDa HA was linked to PE using EDC to achieve a stoichiometry of
1:10 (HA:PE) (A). This ratio was selected because it resulted in the largest
pericellular HA coats, which were detected using fluorescent particle exclusion assays
(B). The black patches on the epi-fluorescent images are areas of pericellular coats.
A Hofmann image is included which shows cells at the center of the pericellular
coats. Images were taken with a 10X objective. The percentage cells/10x field that
were surrounded by HA coats were calculated using Hofmann optics (C). Values are
Mean and S.E.M n = 3 fields. Asterisks indicate statistical significance (p < 0.01).
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Manuscript: Figure 2. Endogenous HA coats require expression of CD44 while HAPE generated coats do not. The numbers of wild type and RHAMM-/- fibroblasts
that form endogenous HA coats are not significantly different. In contrast, loss of
CD44 significantly reduces the numbers of fibroblasts forming coats. This is not further
reduced by loss of both CD44 and RHAMM (A). However, loss of CD44 has no
effect on the number of cells forming coats as a result of HA-PE addition (B). The
pericellular coats formed by CD44-/- fibroblasts in the presence of HA-PE are
destroyed by hyaluronidase (C). Images were taken with a 20X Hoffmann objective.
Values are the Mean and S.E.M. n = 75 cells.
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Manuscript: Figure 3. Topical application of HA-PE stimulates HA accumulation
in wild type and CD44-/- keratinocytes in mouse skin in vivo. Topical application
of HA-PE to shaved B57/BL6 wild type mice increases HA in the keratinocyte layer
as detected by biotinylated HABP (blue staining indicates hyaluronan
detected by HABP probe) (A). Staining 3 days after application is not detectably
different in the dermis and although patchy and variable in the epidermis is
significantly different in HA-PE versus vehicle controls (brown staining indicates
hyaluronan detected by HABP probe) (p < 0.05). Images were taken with a 20X
bright field objective. Similar results were obtained when the epidermal layer was
analyzed for hyaluronan after HA-PE was applied to B57/BL6 RHAMM:CD44-/mice. Significantly greater HA staining was observed in HA-PE treated vs. vehicle
controls (p < 0.0001) (B) Images were taken with a 10X brightfield objective. Values in
A and B are the Mean and S.E.M. n = 3 mice, 5 tissue section/mouse.
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Manuscript: Figure 4. Topical Alexa647-HA-PE enters the epidermis. Significantly
increased fluorescent staining is observed in the epidermis (stratum basale to stratum
granulosum) of the Alexa647-HA-PE group at all time points up to 24 h (mean ± S.E.M,
20 skin images) (* p < 0.05). Representative confocal images of Alexa647-HA-PE
and Alexa647-HA treated mice sectioned at 24 h. Dashed line indicates the junction
of the epidermis and dermis. Arrowheads indicate areas of enhanced pericellular
fluorescence. Alexa647-HA-PE and Alexa647-HA staining was pseudo-colored green.
Blue staining is DAPI.
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Manuscript: Figure 5. HA-PE cream results in a thicker epidermis. There is a
significant increase in epidermal thickness (µm) of mice treated daily with HA-PE
for 1, 5, and 10 days compared with control groups (HA and Vehicle cream) (mean ±
SEM, 5 mice per group) (*p < 0.05). A single representative H&E section from each
of a day 10 HA-PE, HA, and Vehicle Cream mouse is shown, arrows indicate
epidermal thickness.
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Manuscript: Figure

6.

HA-PE

cream

results

in

increased

keratinocyte

proliferation. There is a significant increase in the percentage of positive Ki67 staining
per an area of epidermis of mice treated daily with HA-PE for 1, 5, and 10 days
compared with HA or Vehicle Cream (mean ± SEM, 5 mice per group) (*p < 0.05).
A single representative Ki67 section from each of a day 10 HA-PE, HA, and
Vehicle Cream mouse is shown.
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Manuscript: Figure 7. HA-PE cream does not affect suprabasal keratinocyte
differentiation. The percentage of K10 staining per an area of epidermis for mice
treated daily for 1, 5, and 10 days with either HA-PE, HA, or Vehicle Cream (mean ±
SEM, 5 mice per group).
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Manuscript: Figure 8. HA-PE cream does not elicit a local inflammatory response.
The percentage of positive F4/80 staining per an area of a wounded mouse for mice
treated daily for 1, 5, and 10 days with either HA-PE, HA, or Vehicle Cream (mean ±
SEM, 5 mice per group).
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Manuscript: Figure 9. HA-PE cream does not elicit a local or systemic
inflammatory response. The TNFα expression as a percentage of a wounded mouse
control for day 10 treated mice with HA-PE, HA, or Vehicle Cream using an ELISA
(mean ± SEM, 5 mice per group) (A). The serum CRP concentration (ng/mL) of day
10 treated mice with HA-PE, HA, and Vehicle Cream using an ELISA (mean ± SEM, 5
mice per group) (B).
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Chapter 5: Discussion
Hyaluronan, particularly HMWHA, has proven benefits in wound repair [45, 46, 48], as a
skin surface depot for transdermal drug delivery [92] , and when injected as a cross
linked form, cosmetic tissue rejuvenation [87, 93]. With aging, the quantity of
endogenous HA in the epidermis is decreased and the HA in the dermis becomes more
cross-linked. Topical penetration of exogenous hydrophilic HMWHA has been a
challenge to date because of limited penetration of the negatively charged polymer
through the outer hydrophobic skin layers. This study evaluated the role of a novel
exogenous HA formulation in addressing the functional and aesthetic consequences of
aging. In summary, our study found that modified HA-PE cream penetrated the skin
barrier resulting in increased keratinocyte proliferation and epidermal thickness, without
resulting in a local/systemic inflammatory response compared with control groups
(unmodified HA, vehicle cream).

Our

study

assessed

the

consequences

of

a

novel

hyaluronic

acid

phosphatidylethanolamine (HA-PE) cream (CA Patent PCT/CIPO 2,703,532) designed to
facilitate topical penetration and retention of HMWHA in the skin on keratinocyte
renewal and skin inflammation. HA-PE is a modified hyaluronic acid with approximately
6% of the disaccharide units of native hyaluronan (~500kDa) covalently linked to
phosphatidylethanolamine. Phospholipids, such as PE, act as amphipathic vehicles in skin
delivery with a strong safety profile including low immunogenicity [89]. A stable HA-PE
formulation was accomplished by using the water soluble crosslinking agent, EDC as the
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limiting reagent in the reaction. HA-PE was formulated in a 1:1 (v/v) ratio with a
standard skin base cream and then topically applied to shaved mouse skin.

Evidence that HA-PE cream traversed the outer skin barrier and incorporated into the
epidermal layers was assessed using confocal analysis following a single topical
application Alexa647 fluorescently labeled HA (Alexa647HA and Alexa647HAPE). Our
results show that HA-PE penetrates into the epidermis and is retained for up to 72h
following a single application, suggesting that the amphipathic qualities of the PE linkage
modifications facilitate the permissibility of the 500 kDa HA into the epidermis. These
findings are preserved in CD44-/- mice, demonstrating that the retention of HA-PE
appears independent of CD44 interactions, which is the HA receptor that primarily
mediates endogenous keratinocyte pericellular coats.

Some authors argue that molecules greater than 500 Daltons are impermeable to the skin
barrier [94]. In contrast using a murine model, Brown et al. (1999) showed that
[3H]hyaluronan, weighing approximately 400 kDa, penetrated the skin barrier and small
quantities of 360-400 kDa polymers were recovered in both the skin/blood after
application [95]. The permeability of HA-PE (~500 kDa) likely depended on its structural
composition as opposed to its molecular weight. Modifying the structural composition of
a molecule has been successfully used by other researchers to increase penetration of
hydrophilic compounds. For example, Billich et al. (2005) found that the addition of
phosphocholine to topical Cyclosporin A (1203 Da), an immunosuppressant drug,
increased its penetration into skin compared to an unmodified version [96]. Overall, HA-

85
PE appears to penetrate the skin barrier and be retained in the extracellular space
independent of CD44 receptor interactions.

The addition of phosphatidylethanolamine to HA-PE results in retention of exogenous
HA-PE in the epidermis. The retention of HA-PE is likely a result of interactions with
receptors, inserting into the plasma membrane via the PE tails and native HA in the extracellular environment. The rate of HA-PE rate of decline appears reduced compared to
unmodified HA, however this was not measured directly and should be the focus of
future investigations. Native epidermal HA turnover (t1/2) is approximately 24h [41, 97].
Our findings are consistent with these previous results with declining levels of both
exogenous HA-PE and HA occurring 24h after a single application. Overall, HA-PE
cream delivers HMWHA to the epidermis, which behaves in a similar fashion to native
HA.

Qualitatively in addition to accumulating in the basal keratinocyte layer of the epidermis,
a strong signal for HA-PE remained in the SC up to the final 72h time point. In addition
to a role in providing a permeability barrier, the SC is important in preventing xerosis [7].
Skin hydration in the SC is dependent on the configuration of lipids and the presence of
hygroscopic molecules such as NMF [98] . Saki et al. (2000) deposed earlier theories that
hyaluronan was absent from SC [99]. Their group provided evidence that along with
NMF, HA was a key player in the moisturization of the outermost layer of the epidermis
[99]. In addition to providing a reliable carrier of HMWHA to the epidermis, retention of
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HA-PE in the SC has the potential added benefit of improving skin hydration through
reinforcing the outermost protective barrier.

Further evidence supporting the penetration of HA-PE into the epidermis rests in its
effect on epidermal physiology. Multiple applications of HA-PE result in a two-fold
increase in epidermal thickness compared with unmodified HA. This increase in
epidermal thickness correlates to increased keratinocyte proliferation without detectable
differences in suprabasal terminal keratinocyte differentiation per area. The thickened
epidermis is likely to reflect both indirect (hydrophilic properties of HA, not measured in
the current study) and direct (stem cell mobilization/cell proliferation) effects of HA-PE
cream. Thus, the increased keratinocyte proliferation observed in the current study is
likely secondary to stimulation of EPUs in the basal layer of the epidermis by HA-PE.
However, the exact mechanism and confirmation of the effect of HA-PE on EPU is a
potential topic for future study.

Stimulation of epidermal proliferation may be negatively linked to either tumorigenesis
or hyperproliferative skin disorders such as psoriasis. Skin tumor biology is complex.
Repetitive ultraviolet radiation damage is widely known to be an important risk factor for
the development of basal and squamous cell cancers. It is unlikely that HMWHA
promotes skin tumorigenesis. First, HMWHA acts as a free radical scavenger and is
protective against DNA damage which is a common etiology linked to skin cancer [100].
In a rodent model, HMWHA production in the naked mole rat confers resistant to cancer
throughout its extended lifespan (30+ years) [51]. When production of HMWHA is
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blocked, the cancer resistance is lost. However, future research is needed to refute any
unlikely potential link with HA-PE cream application and tumorigenic potential. In terms
of promoting a negative hyperproliferative skin phenotype, fortunately, the structure of
the skin layer histology appears qualitatively to remain intact following HA-PE cream
application. In comparison, marked hyperplasia of the epidermis and incomplete
keratinocyte differentiation can be negatively associated characteristics of psoriasis-like
skin inflammation. In psoriasis these changes are also accompanied by a loss of the
granular cell layer of the epidermis in addition to the presence of neutrophils in the
epidermis[90], which are not changes evident in our experimental model.

One potential mechanism by which topical HA-PE recovers an attenuated epidermis is by
attracting water to the ECM. HA can bind up to 10,000x its weight in water [100].
Exogenous HA-PE traverses the skin barrier and contributes to the keratinocyte
pericellular coat mimicking an endogenous HA configuration. Röck et al. (2010)
demonstrated that intradermal injection of non-crosslinked HA incorporated into the
pericellular matrix and promoted proliferation of fibroblasts in vitro [101]. Similarly, our
non-crosslinked topical HA-PE transverses the skin barrier and incorporates into the
pericellular matrix. The immediate increase in epidermal thickness evident at 24h postapplication may therefore reflect the increased water content of the epidermis treated with
HA-PE.

Thinned epidermis characteristic of senescent skin, in both human and murine models, is
a result of decreased keratinocyte proliferation [2, 3, 56]. Topical HA-PE has a direct
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effect on restoring the proliferative capacity of aged keratinocytes contributing to a
thickened epidermis. Pericellular hyaluronan coats are known to create a fluid scaffold,
which enhances cell migration and proliferation [28, 43]. Exogenous HA-PE may
facilitate diffusion and interactions of keratinocyte growth and differentiation factors in
the restored pericellular matrix. Alternatively, a mechanical stimulus from increased
ECM volume may exist which stimulates keratinocyte proliferation. The added ECM
structural support from crosslinked dermal HA fillers have been associated with a modest
increase in epidermal thickness one to three months post-injection [14]. The added ECM
volume from HA-PE could incite a similar stimulus for epidermal proliferation. Our
findings of HMWHA resulting in increased keratinocyte proliferation conflict with the
results from studies which show only LMWHA and not HMWHA enhance keratinocyte
proliferation in aged skin [56, 62]. For example, Kaya et al. (2006) used in vivo and in
vitro models to demonstrate that only topical HA cream < 400 kDa resulted in
keratinocyte proliferation and skin hyperplasia, whereas HA > 400 kDa had no effect.
This finding could be due to poor penetration of HA > 400 kDa in their experimental
models

which

included

both

mouse

and

human

skin.

The

addition

of

phosphatidylethanolamine in the HA-PE cream overcomes penetration barriers allowing
HMWHA to enter the skin and impact downstream mediators of skin rejuvenation and
growth.

Topical HA-PE: HA receptor interactions, may also promote up-regulation of
endogenous HA production to further amplify its effects and establish a positive
autocrine feedback loop.

In support of this injected HA has been shown to have a
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stimulatory effect on endogenous synovial cell HA synthesis [102] . Rilla et al. (2013)
demonstrated that activate HA synthesis is associated with cells shedding microvesicles
containing HA synthetic machinery which can propagate HA production at a distance
from the original cell source [103]. Therefore, HA-PE could promote HA production in
the dermis and other points distance from the epidermis by this type of mechanism.
Further studies are required to elucidate potential mechanism whereby exogenous HA-PE
restores a critical quantity of HA in the epidermis, which is permissive to functional
activation of endogenous HA synthesis.

Consistent with my results, previous studies have indicated increased keratinocyte
proliferation and thickened epidermis can result from factors that promote HA synthesis,
such as EGF, whereas factors that inhibit HA synthesis result in decreased proliferation
and enhanced differentiation [21]. Our results show despite increased proliferation there
was no detectable difference per area of suprabasal keratinocyte differentiation compared
with control groups. Thus, the downstream signaling effects of HA-PE stimulate
keratinocyte proliferation without negatively affecting the suprabasal differentiation
expression. This is important because preservation of keratinocyte differentiation is
crucial to maintain epidermal integrity [104].

If exogenously applied HMWHA is rapidly metabolized into pro-inflammatory LMWHA
fragments it has the potential for stimulating inflammation. Our study has provided
evidence that topical HA-PE cream does not elicit either a local or systemic inflammatory
response. In mimicking the endogenous configuration of HA, HA-PE preserves the anti-
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inflammatory properties of HMWHA. The wounding literature best supports the antiinflammatory nature of HMWHA. Topical HMWHA added to a rat laminectomy model
before final skin closure resulted in a reduction of macrophages and inflammatory
cytokines at the wound site during the acute phase of healing [82]. Schimizzi et al. (2006)
theorized that HMWHA blocked the interaction of LMWHA pro-inflammatory signaling
cascades [82]. In addition, the hydrophilic properties of HMWHA were thought to
provide a dilutional effect on inflammatory cell mediators [82]. The anti-inflammatory
properties of HA have been used clinically as a component in wound dressings for burns
and skin ulcers since the 1960s [71, 102]. Injectable HA has also been used as a therapy
to temporize joint inflammation in arthritis [102]. In addition, HMWHA has well
documented anti-oxidant properties as a free radical scavenger which protects cellular
DNA from damage [105]. Our study has confirmed the absence of an inflammatory
reaction caused by HA-PE cream when applied to normal aged skin. However, future
studies are needed to determine if anti-inflammatory and anti-oxidant properties of HAPE cream have benefit in clinical models of cutaneous inflammation or wounding.
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Limitations and Future Directions
One of the limitations of the current study is technical. A wild-type murine model of aged
skin was chosen because unlike nude murine models, the wild-type mice have the full
compliment of their immune system. Compared with human skin, the mouse epidermis
and dermis are thinner and thus penetration of the experimental creams may be
facilitated. However, due to economic and practical administrative reasons of a pilot
study, more homologous models to human skin were not selected. In addition, as this is a
pilot experiment, the variability of the expected findings was not known at the time of
model selection. Extrapolating the study results broadly to other animal models or
humans should be done with caution. We recommend that future studies repeat and add
to our results in a model whose skin more closely resembles that of human tissue. In
addition, given the proven beneficial effects of HMWHA on certain pathologic
conditions such as radiation dermatitis, burns, cutaneous wounds, and ulcers, it would be
interesting to study whether topical HA-PE had a beneficial effect in these settings.

Another limitation is confirming if HA promotes skin renewal by mobilizing stem cell
and/or TA populations in the basal layer of the epidermis. Future studies could
incorporate markers of stem cell populations such as integrins[106] or Oct4[19] to further
evaluate this theory.

Skin integrity and health is a multidimensional construct. For our studies, we selected a
handful of relevant markers as a starting point to understand the potential effects of HAPE cream on the epidermis. However, further research is needed to explore additional
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markers of skin integrity and dermal markers. Our results suggest that HA-PE penetrates
through the dermis but we did not test for its effects in this layer. Future studies for
example could use markers of collagen production or Flaggrin expression in the SC could
provide further support of the trophicity of HA-PE on aged skin. In addition, it will be
necessary for future studies to examine the potential mechanisms of action of HA-PE.
Examining known pathways of native HA activity could help elucidate whether HA-PE is
acting through an analogous mechanism.

Our analysis methodology included primarily immunohistochemistry and ELISA tissue
specimens. Given that these methodologies rely on preserved and dehydrated specimensthey can only at best provide a snapshot of the dynamic state of live tissue. Furthermore,
the immunohistochemistry analysis software relies on calculating pigment density as an
indicator of the presence of the markers of interest. There is always some variability in
the uptake and penetration of the stain given a particular staining cycle and the particular
section of tissue. To mitigate this variability, all specimens from a single time point were
stained and analyzed as a cohort.

Given that HA is known to improve cutaneous hydration and barrier function- we
recommend that future studies consider adding a functional measure of cutaneous
hydration and transepidermal water loss (TEWL) in a live animal model. In the current
study, the necessary equipment for these measurements was cost prohibitive to obtain for
the pilot data.
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The current investigation provides a foundation for future studies to investigate the
positive effect of HA-PE on replacing the native cutaneous HA lost with age.

Conclusion
Aged skin, characterized by diminished hyaluronan, has both functional and aesthetic
deficits. Topical HA-PE is a novel skin care technology that reliably carries HMWHA
(500 kDa) into the epidermis to restore a youthful phenotype to aged skin. The biological
effect of HA-PE results in a thicker epidermis from enhanced keratinocyte proliferation.
The suprabasal differentiation markers appear unchanged compared to unmodified HA.
In addition, HA-PE does not result in either a local or systemic inflammatory response.
Findings from our investigation provide a foundation for further research to elucidate
additional clinically relevant benefits of HA-PE cream.
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Appendix B

Supplemental: Figure 1. Epidermal thickness representative H&E sections from each
of day 1 HA-PE (A), HA (B), and Vehicle Cream (C) groups.
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Supplemental: Figure 2. Epidermal thickness representative H&E sections from each
of day 5 HA-PE (A), HA (B), and Vehicle Cream (C) groups.
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Supplemental: Figure 3. Ki67 representative sections from each of day 1 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. Ki67 – brown staining.
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Supplemental: Figure 4. Ki67 representative sections from each of day 5 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. Ki67 – brown staining.
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Supplemental: Figure 5. K10 representative sections from each of day 1 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. K10 – brown staining.
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Supplemental: Figure 6. K10 representative sections from each of day 5 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. K10 – brown staining.
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Supplemental: Figure 7. K10 representative sections from each of day 10 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. K10 – brown staining.

113

Supplemental: Figure 8. F4/80 representative sections from each of day 1 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. F4/80 – brown staining.
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Supplemental: Figure 9. F4/80 representative sections from each of day 5 HA-PE (A),
HA (B), and Vehicle Cream (C) groups. F4/80 – brown staining.
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Supplemental: Figure 10. F4/80 representative sections from each of day 10 HA-PE
(A), HA (B), and Vehicle Cream (C) groups. F4/80 – brown staining.
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Epidermis

Dermis

Subcutaneous
Tissue

Supplemental: Figure 11. F4/80 representative sections from wounded mouse positive
control. F4/80 – brown staining.
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